Water-soluble chlorophyll protein as efficient photosensitizer for cancer photodynamic therapy

WO2024175997A3PCT designated stage expired Publication Date: 2024-11-14THE HONG KONG UNIV OF SCI & TECH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/000091
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-20
Filing Date
2024-02-20
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current photosensitizers for photodynamic therapy (PDT) face limitations such as poor water solubility, high toxicity, photo-instability, and non-biodegradability, which restrict their clinical applications for cancer treatment.

Method used

Development of a water-soluble chlorophyll protein (WSCP) complex, expressed in Escherichia coli and purified to form a stable tetrameric complex with spinach chlorophylls, which acts as a biocompatible and photo-stable photosensitizer generating reactive oxygen species upon red-light irradiation.

Benefits of technology

The WSCP complex demonstrates superior stability, non-toxicity, and biocompatibility, effectively inducing cell death in cancer cells with minimal phototoxicity to normal cells, paving the way for wider clinical applications of PDT.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

Provided is a safe and effective photosensitizer that expands the clinical use of photodynamic therapy (PDT) as a non-invasive cancer treatment. Specifically, Provided are methods of using water-soluble chlorophyll protein (WSCP) as a new photosensitizer for cancer phototherapy. Advantageously, WSCP is stable, non-toxic, and biocompatible while generating reactive oxygen species, making it useful for deep-tissue PDT.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] TITLE WATER-SOLUBLE CHLOROPHYLL PROTEIN AS EFFICIENT PHOTOSENSITIZER FOR CANCER PHOTODYNAMIC THERAPY

[0003] CROSS-REFERENCE TO RELATED APPLICATION

[0004] The subject application claims the benefit of U.S. Provisional Application Serial No. 63 / 485,928, filed February 20, 2023, which is incorporated herein by reference in its entirety.

[0005] SEQUENCE LISTING

[0006] The Sequence Listing for this application is labeled “HKUS.188XPCT.xml,” which was created on February 9, 2024, and is 2,031 bytes. The Sequence Listing is incorporated herein by reference in its entirety.

[0007] BACKGROUND OF THE INVENTION

[0008] Photodynamic therapy (PDT) is an effective and noninvasive modality for treatment of cancers and has been in clinical practice (cancer treatment) for more than 40 years.1'4PDT has been commonly used for treatment of cutaneous tumors (precancerous keratosis skin lesions and some non-melanoma skin cancers)5,6and holds great promise in treatment of various other cancer types including breast, lung, bladder, pancreas, cervix, prostate, and brain.1'3,7,8As compared to other conventional protocols (surgery, chemotherapy, and radiotherapy), PDT has demonstrated significant clinical advantages such as minimal invasiveness, little drug resistance, and high spatiotemporal precision and thus become a complementary local therapeutic modality in a combination of chemo-9and immune- therapies10.

[0009] The therapeutic mechanism of PDT employs three essential components: light, photosensitizer (PS), and oxygen to generate reactive oxygen species (ROS), which cause damages to biological molecules such as proteins, nucleic acids, and lipids and thus induce cell death (mostly likely through apoptosis).11,12Decisive to the PDT therapeutic efficacy is the light-oxygen connecting component photosensitizer, which is excited by light and react with oxygen to generate the deadly cell-killing ROS (singlet oxygen or hydroxyl / hydroperoxyl radical via either energy or electron transfer, respectively).12,13As a result, hundreds of photosensitizers have been studied and tested clinically for tumor destruction

[0010] Notably, most photosensitizers are structurally based on tetrapyrrole backbone8(porphyrin13,18,20, chlorin17’21’22, bacteriochlorin17’21, and phthalocyanine23), which can be excited with tissue-penetrating red light at 650-900 nm (therapeutic window19). Representative examples include the very first photosensitizer termed “hematoporphyrin derivative” (HpD) for PDT treatment of cutaneous and subcutaneous tumors24, clinically approved photofrin (porfimer sodium, a major purified component of HpD) for oesophageal, bladder, and lung cancers, and the second-generation chlorin-based anticancer photosensitizers such as temoporfin (Foscan for head and neck tumor), verteporfm (Visudyne), talaporfin (LSI 1), padeliporfin (Tookad), photochlor (clinical trial), redaporfm (clinical trial), and fimaporfm (clinical trial).1,13However, both porphyrin and chlorin photosensitizers for PDT suffer from one or more of the many drawbacks: poor water solubility, high (photo-)toxicity, photo-instability, and / or non-biodegradability, which account for the overall disappointing progress of clinical PDT for cancer treatment.1,8,25,26

[0011] As compared to porphyrins (HpD and photofrin) with weak absorption peak at 630 nm (Q-band), the chlorin-based photosensitizers (chlorophyll derivatives such as temoporfin and talaporfin) absorb light at >650 nm (characteristic of chlorin) with deep-tissue penetrating ability and higher potency (lower dose).27Importantly, chlorin-based photosensitizers can be cleared out quickly by metabolism and have shorter time of skin photosensitivity.8,27,28These advantages make chlorin photosensitizers more attractive for PDT as evident with that many second-generation photosensitizers are chlorins being tested / approved for tumor ablation.8,29,30However, either solubility or stability / toxicity remains unsolved: the better water solubility by either structural modification of chlorophylls or chemical synthesis of chlorin photosensitizers is often compromised by poor stability and / or high toxicity.8

[0012] The naturally occurring chlorins such as the most abundant chlorophylls (magnesium- complexed chlorins), are nontoxic but water-insoluble and thermo- / photo-unstable.17While polymers31(i.e., hydrogel) and nanomaterials32(i.e., metal nanoparticles) have been designed as drug carriers of chlorophylls for PDT to improve water solubility and photostability14,22, the safety concerns about long-term toxicity and biodegradability (body clearance of these polymers / nanomaterials in human body) restrain their biomedical applications.8,33 The development of safe and effective photosensitizers is critical for expanding the clinical use of photodynamic therapy (PDT) as a non-invasive cancer treatment. Because the photosensitizers used for PDT are still suffering from one or more of the many common limitations such as phototoxicity, photo / thermostability, and biocompatibility, which restrains PDT from large-scale clinical applications, there is a need to develop and identify novel photosensitizers for cancer treatment.

[0013] BRIEF SUMMARY OF THE INVENTION

[0014] The subject invention provides products, compositions, and methods for treating cancer using PDT. In one embodiment, the subject invention provides photosensitizers / photosensitizing agents for use in photodynamic therapy.

[0015] The present invention pertains to the development of the water-soluble chlorophyll protein (WSCP) as a new photosensitizer for cancer phototherapy. WSCP is a stable, water- soluble, nontoxic tetrameric complex containing 2-4 chlorophylls, which serves as a stable photosensitizer to generate reactive oxygen species (ROS or singlet oxygen) for inducing cell death. Advantageously, WSCP can be used to solve the long-lasting plaguing paradox of compromising solubility with stability / toxicity from chlorin-based photosensitizers. Systemic studies showed that the recombinant WSCP not only overcomes traditional photosensitizers’ drawbacks of water-solubility, toxicity, and biocompatibility but also displays superior stability with strong absorption at, for example, the 660 nm red light for deep-tissue PDT.

[0016] In the present invention, WSCP was expressed in Escherichia coli and was purified as a monomeric apoprotein, which bind with chlorophylls (from spinach) in vitro to form a stable green tetrameric WSCP complex. Spectroscopic studies indicate that this recombinant WSCP is water-soluble, photo- / thermostable, and most importantly as photosensitizers capable of generation of singlet oxygen upon red-light irradiation under oxygen condition. The bioassay studies suggest that WSCP is an effective photosensitizer for PDT in the in vitro and in vivo treatment of cancers with no dark cytotoxicity, and with limited phototoxicity towards normal cells. The results demonstrate the practical utility of WSCP in PDT for tumor destruction and lays the groundwork for further clinical trials and use.

[0017] The subject invention established the water-soluble recombinant WSCP complex as an efficient and biocompatible photosensitizer for in vitro and in vivo photodynamic therapy for cancers. The recombinant WSCP features the integration of water-soluble biopolymers and organic photosensitizers (chlorophylls). The formation of tetrameric protein complexes greatly stabilizes the unstable chlorophylls with retention of their ability as a photosensitizer to generate reactive oxygen species (ROS, singlet oxygen) upon light irradiation for PDT. The use of WSCP for PDT overcomes many existing limitations of photosensitizers including water-solubility, photo / thermostability, dark-toxicity, biocompatibility, and biodegradability, which will open the door to wider clinical applications.

[0018] In some embodiments, the subject invention provides photosensitizers / photosensitizing agents, and compositions comprising them for use in methods of PDT for causing photodynamic damage to cancer cells and thereby treating cancer. Photodynamic damages to cancer cells include, but are not limited to, preventing or reducing the development of a cancer, reducing the symptoms of cancer, suppressing or inhibiting the growth of an established cancer, preventing metastasis and / or invasion of an existing cancer, promoting or inducing regression of the cancer, inhibiting or suppressing the proliferation of cancerous cells, and reducing angiogenesis or increasing the amount of apoptotic cancer cells.

[0019] In one embodiment, the subject invention provides a pharmaceutical composition for use in PDT comprising a water-soluble chlorophyll protein (WSCP) complex, wherein the WSCP complex comprises a water-soluble chlorophyll protein and 2-4 chlorophylls.

[0020] In one embodiment, the subject invention provides a method of PDT for treating cancer, the method comprising administering to a subject in need of such therapy an effective amount of a WSCP complex or a pharmaceutical composition comprising the WSCP complex; and irradiating cancer by exposing the WSCP complex to an excitation light.

[0021] In one embodiment, the WSCP complex comprises a WSCP and 2-4 chlorophylls, wherein the WSCP complex serves as a stable photosensitizer to generate reactive oxygen species for inducing cell death.

[0022] In a specific embodiment, the WSCP comprises an amino acid sequence of SEQ ID NO: 1, biologically-active fragments, variants thereof, or an amino acid sequence sharing at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 1.

[0023] In one embodiment, the WSCP complex is administered intravenously, intraperitoneally, intramuscularly, intratumorally, intraarterially, topically, and / or orally.

[0024] In one embodiment, the subject invention provides a method for photodynamically damaging cancer cells, the method comprising contacting the cancer cells with an effective amount of a WSCP complex or a pharmaceutical composition comprising the WSCP complex; and irradiating the cancer cells with an excitation light.

[0025] In one embodiment, the subject invention provides a method for inhibiting the proliferation of cancer cells, the method comprising contacting the cancer cells with an effective amount of a composition comprising a WSCP complex; and irradiating the cancer cells with an excitation light.

[0026] In one embodiment, the excitation light has a wavelength ranging, for example, from about 400 nm to about 900 nm, from about 450 nm to about 850 nm, from about 500 nm to about 800 nm, from about 550 nm to about 750 nm, from about 600 nm to about 700 nm, from about 600 nm to about 800 nm, from about 600 nm to about 900 nm, from about 700 nm to about 800 nm, from about 800 nm to about 900 nm, from about 700 nm to about 900 nm, from about 400 nm to about 700 nm, from about 400 nm to about 600 nm, from about 500 nm to about 700 nm, from about 500 nm to about 600 nm, or from about 400 nm to about 500 nm. In a preferred embodiment, the excitation light has a wavelength ranging from about 600 to about 700 nm. In a specific embodiment, the light is white light or red light.

[0027] In one embodiment, the subject invention provides a method for inhibiting the proliferation of cancer cells, the method comprising contacting the cancer cells with an effective amount of a WSCP complex comprising a WSCP and 2-4 chlorophylls; and irradiating the cancer cells with an excitation light having a wavelength of about 600-900 nm.

[0028] BRIEF DESCRIPTION OF THE DRAWINGS

[0029] FIGs. 1A-1F. Property characterization of the recombinant WSCP: FIG. 1A Normalized absorption and emission (excited at 634 nm) profile of the recombinant WSCP in H2O. FIG. IB Normalized absorptions of 9,10-anthracenediyl-bis(methylene) dimalonic acid (ABDA) (c = 2* 10'5M) in H2O upon white-light (W.L.) (1 mW / cm2) or 660 nm red light (7 mW / cm2) irradiation in the presence of different photosensitizers (c = P I O-4M): WSCP, Rose Bengal or Ce6 (porphyrin derivative). FIG. 1C Infrared thermal images of the recombinant WSCP (2 mg / mL) in H2O upon light irradiations (660 nm, 0.8 W / cm2). FIG. ID Photothermal conversion performance of the recombinant WSCP at different concentrations in H2O upon light irradiation (660 nm, 0.8 W / cm2). FIG. IE Photothermal stability of the recombinant WSCP (3 mg / mL) in H2O within four cycles of light irradiation (660 nm, 0.8 W / cm2). FIG. IF Comparison between long-term stabilities of free chlorophylls and the recombinant WSCP in H2O under ambient conditions. FIGs. 2A-2G. Light-induced in vitro cytotoxicity of the recombinant WSCP against cancerous cells: FIG. 2A Representative micrographs showing the influence of the recombinant WSCP on HeLa cells upon 660 nm red light (7.0 mW / cm2) irradiation. Scale bar: 40 / / m. FIG. 2B Relative viability and ICso of HeLa cells after incubation with recombinant WSCP with or without 660 nm red light irradiation (63.3 mW / cm2) for different time. Data were expressed as the mean ± SD with three independent experiments. FIG. 2C Relative viability and ICso of HeLa cells after incubation with recombinant WSCP with or without 660 nm red light irradiation with different lighting power density for 30 min. Data were expressed as the mean ± SD with three independent experiments. FIG. 2D Colony formation assay was performed to study the long-term effects of recombinant WSCP photoinduced therapy on the survival and proliferation of HeLa cells. In vitro phototherapy with recombinant WSCP inhibited the colony forming ability of HeLa cells in a concentrationdependent manner. FIG. 2E Recombinant WSCP inhibited the migration of HeLa cells after treatment with irradiation. Scale bar: 40 / / m. FIG. 2F Relative viability of HeLa Cells after incubation with the recombinant WSCP in the present or absent of N-acetyl-L-cysteine (NAC, a ROS inhibitor) with light irradiation. FIG. 2G In vitro photocytotoxicity of recombinant WSCP toward different cell lines. Data were expressed as the mean ± SD with three independent experiments.

[0030] FIGs. 3A-3D. Study of intracellular ROS generation capability and cellular uptake of recombinant WSCP: FIG. 3A Confocal microscopy images of HeLa cells after different corresponding treatments, and 2',7'-dichlorofluorescin diacetate (DCF-DA) was used for intracellular ROS staining. Scale bar: 50 / / m. FIG. 3B Flow cytometric analysis of intracellular ROS generation. FIG. 3C Flow cytometric analysis of uptake of recombinant WSCP by HeLa cells. FIG. 3D Representative images showing the cellular uptake of recombinant WSCP with the passage of time. Scale bar: 10 / / m.

[0031] FIGs. 4A-4H. In vivo anticancer activity evaluation of recombinant WSCP in tumor xenograft mouse model: FIG. 4A Schematic illustration of in vivo photo-induced anticancer activity evaluation of recombinant WSCP. FIG. 4B Change of body weight of mice during the treatment. FIG. 4C Tumor volume change of mice during the treatment. FIG. 4D Comparison of tumor volume of mice between control group and intratumorally injection group. FIG. 4E Tumor weight of the killed mice after treatment. FIG. 4F Photo of tumor of the killed mice after treatment. FIG. 4G Organ index of heart, liver, spleen, lung, kidney, thymus tissue of different treatment groups. FIG. 4H Photos of Organ tissue slices of different treatment groups. Scale bar: 40 pm.

[0032] FIG. 5. Normalized absorptions of 9,10-anthracenediyl-bis(methylene) dimalonic acid (ABDA) (c = 2* 10'5M) in H2O upon white-light (1 maw / cm2) or 660 nm red light (7 mW / cm2) irradiation in the presence of different photosensitizers (c = P I O'4M): WSCP, Rose Bengal or Ce6 (porphyrin derivative).

[0033] FIG. 6. Infrared thermal images of recombinant WSCP (2 mg / mL) in H2O upon light irradiations (660 nm, 0.8 W / cm2).

[0034] FIG. 7. Comparison between long-term stabilities of free chlorophylls and recombinant WSCP at ambient condition.

[0035] FIG. 8. Colony formation assay was performed to study the long-term effects of recombinant WSCP photo-induced therapy on the survival and proliferation of HeLa cells and A549 cells.

[0036] FIG. 9. Wound healing assay results of HeLa cells and A549 cells.

[0037] FIG. 10. Relative viability and IC50 of HeLa cells after incubation with recombinant WSCP with or without 660 nm red light irradiation (63.3 mW / cm2) for different irradiation time. Data were expressed as the mean ± SD with three independent experiments.

[0038] FIG. 11. Relative viability and IC50 of HeLa cells after incubation with recombinant WSCP with or without 660 nm red light irradiation (30 min) with different lighting power density. Data were expressed as the mean ± SD with three independent experiments.

[0039] FIG. 12. In vitro photocytotoxicity of recombinant WSCP toward different cell lines.

[0040] FIG. 13. Cell viabilities of HeLa cells incubated with the recombinant WSCP upon light irradiation.

[0041] FIG. 14. Cell viabilities of A549 cells incubated with the recombinant WSCP upon light irradiation.

[0042] FIG. 15. Cell viabilities of L02 cells incubated with the recombinant WSCP upon light irradiation.

[0043] FIG. 16. Cell viabilities of SKOV3 cells incubated with the recombinant WSCP upon light irradiation.

[0044] FIG. 17. Cell viabilities of 4T1 cells incubated with the recombinant WSCP upon light irradiation.

[0045] FIG. 18. Cell viabilities of Hep G2 cells incubated with the recombinant WSCP upon light irradiation. FIG. 19. Cell viabilities of HeLa cells after incubation with the high concentration WSCP for 48 h in darkness.

[0046] FIG. 20. Confocal microscopy images of HeLa cells after different corresponding treatments, and 2',7'-dichlorofluorescin diacetate (DCF-DA) was used for intracellular ROS staining. Scale bar: 50 pM.

[0047] FIG. 21. Confocal microscopy images of HeLa cells incubated with the recombinant WSCP (150 pg / mL) for24 h. Scale bar: 10 pM.

[0048] FIG. 22. Confocal microscopy images of normal liver cells (L02) after incubated with WSCP for different time. Scale bar: 20 pM.

[0049] FIG. 23. Confocal microscopy images of unfixed HeLa cells incubated with or without the recombinant WSCP (150pg / mL) for 24 h upon irradiation of confocal microscope. Scale bar: 10 pM.

[0050] BRIEF DESCRIPTION OF THE SEQUENCES

[0051] SEQ ID NO: 1 is an amino acid sequence of WSCP contemplated for use according to the subject invention.

[0052] DETAILED DISCLOSURE OF THE INVENTION

[0053] The subject invention provides products, compositions, and methods for treating cancer using PDT. In one embodiment, the subject invention provides photosensitizers / photosensitizing agents for photodynamic therapy. In specific embodiments, the subject invention provides a water-soluble chlorophyll protein (WSCP), which is a stable, water-soluble, chlorophyll-binding protein forming a chlorophyll-protein complex, for use as photosensitizers / photosensitizing agents for in vitro and in vivo photodynamic therapy for cancers. Compared to traditional photosensitizers, WSCP and / or WSCP complex exhibits superior stability, non-toxicity, and biocompatibility while generating reactive oxygen species for inducing cancer cell death in response to red light, making it well-suited for deeptissue PDT.

[0054] In one embodiment, the subject invention discloses the use of WSCP as a new photosensitizer for cancer phototherapy. The subject invention provides a novel strategy for overcoming the limitations of traditional photosensitizers and PDT using WSCP. The present invention has significant implications for advancing cancer treatment and improving patient outcomes. In certain embodiments, the subject invention provides a water-soluble recombinant WSCP complex as an efficient and biocompatible photosensitizer for in vitro and in vivo photodynamic therapy for cancers. The water-soluble recombinant WSCP complex features the integration of water-soluble biopolymers and organic photosensitizers (e.g., chlorophylls). The formation of tetrameric protein complexes greatly stabilizes the unstable chlorophylls with retention of their ability as a photosensitizer to generate reactive oxygen species (ROS, singlet oxygen) upon light irradiation for PDT.

[0055] Advantageously, the use of WSCP for PDT overcomes many existing limitations of photosensitizers including water-solubility, photo / thermostability, dark-toxicity, biocompatibility, and biodegradability, which indicates wide applications of WSCP.

[0056] In one embodiment, the photosensitizer / photosensitizing agent of the subject invention for use in PDT comprises a water-soluble biopolymer and one or more organic photosensitizers (e.g., chlorophylls). In a further embodiment, the water-soluble biopolymer is a peptide and / or protein that can bind to the one or more organic photosensitizer, preferably, two to four organic photosensitizer, to form a complex.

[0057] In a specific embodiment, the photosensitizer / photosensitizing agent of the subject invention for use in PDT is a WSCP complex according to the subject invention, which comprises a water-soluble WSCP and one or more chlorophylls. In a specific embodiment, the photosensitizer / photosensitizing agent is a tetrameric WSCP complex. Remarkably, such tetrameric WSCP complex is still highly soluble in water and exhibits extraordinary thermostability and astounding photostability. In contrast, free chlorophylls (naturally occurring chlorins) as photosensitizers are insoluble in water and quite unstable (green color fading within a day) due to photooxidation in the presence of air (molecular oxygen). Importantly, the tetrameric WSCP complex retains the ability as photosensitizers for converting ground-state oxygen (3O2) to single oxygen (1O2).

[0058] In a preferred embodiment, the water-soluble biopolymer is WSCP. In a specific embodiment, the WSCP comprises an amino acid sequence of SEQ ID NO: 1, biologically- active fragments, variants thereof, or an amino acid sequence sharing at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 1.

[0059] In a preferred embodiment, the organic photosensitizer is chlorophyll.

[0060] In certain embodiments, the photosensitizing agent can be excited at 400-900 nm, preferably, 600-900 nm, more preferably, 600-700 nm. In a specific embodiment, UV-vis spectra of the recombinant WSCP exhibits intense absorption band in the range of 350 - 480 nm and 600-700 nm with the maxima at 435 and 665 nm and photoluminescence (PL) spectra of the recombinant WSCP displayed a maximal emission peak at 684 and 735 nm (excited at 634 nm).

[0061] In certain embodiment, WSCP demonstrated a significantly higher efficiency ROS [x lO-3s'1] of singlet oxygen generation than that of Rose Bengal (6.44 upon white light irradiation) and Ce6 (1.3 upon white light irradiation; 2.3 upon red light irradiation) under either white light or red light irradiation within the same irradiation time. The astonishing efficiency of singlet oxygen generation at 660 nm red light irradiation renders WSCP advantageous to PDT application for cancer treatment.

[0062] Advantageously, the extraordinary photothermal stability distinguished the recombinant WSCP of the subject invention from the majority of organic photosensitizers (e.g., porphyrins and chlorins) in PDT. Also, the recombinant WSCP of the subject invention exhibits extremely low dark-cytotoxicity. Thus, the recombinant WSCP of the subject invention shows unexpected selectivity of cancer cells over normal cells, which can be due to 1) different cell sensitivity to singlet oxygen and 2) the difference in possible cellular uptake of the recombinant WSCP. This selectivity can reduce the damage to normal tissues and would be advantageous and significant in the clinical application of PDT with WSCP.

[0063] In certain embodiments, the organic photosensitizer is capable of absorbing visible light to emit fluorescence and generating active oxygen. Preferably, the organic photosensitizer is a tetrapyrrole-based compound. Specific examples thereof include, but are not limited to, photofrin, Laserphyrin, protoporphyrin IX, Foscan, chlorins, uroporphyrin I, uroporphyrin III, heptacarboxylporphyrin I, heptacarboxylporphyrin III, hexacarboxylporphyrin I, hexacarboxylporphyrin III, pentacarboxylporphyrin I, pentacarboxylporphyrin III, coproporphyrin I, coproporphyrin III, isocoproporphyrin, harderoporphyrin, isoharderoporphyrin, hematoporphyrin, mesoporphyrin, etioporphyrin, pyrroporphyrin, deuteroporphyrin IX, pemptoporphyrin, and ATXs-10.

[0064] In one embodiment, the photosensitizing agent of the subject invention contains a photosensitizer useful for causing photodynamic damage to cancer cells. Damage, as used herein, includes destruction of cellular organelles and subsequently suppression of cell growth, suppression of cell growth rate, and / or cell death.

[0065] In some embodiments, upon irradiation, the photosensitizer molecules are excited to a singlet state. Following excitation, fast radiationless relaxation to the lower-lying triplet states occurs. The longer the decay lifetime of the triplet state, the more time the photosensitizer has to act on a tissue, such as a tumor tissue and to initiate biochemical and biophysical mechanisms, which cause tumor necrosis.

[0066] In certain embodiments, the photosensitizer can be a macrocyclic organic complex, which absorbs wavelengths in the range of from about 300 nm to about 900 nm, typically from about 400 nm to about 800 nm. These photosensitizers are capable of transferring their absorbed energy to molecular oxygen to generate singlet oxygen. Examples of suitable macrocyclic organic complexes include, but are not limited to, porphyrin and their derivatives, pyrrole, tetrapyrollic compound, expanded pyrrolic macrocycle and their derivatives, cyanine and their derivatives, flavin, organometallic species, nanoparticle, or combinations thereof.

[0067] Representative examples of suitable macrocyclic compounds include, but are not limited to, green porphyrins, protoporphyrin, chlorins, tetrahydrochlorins (chlorins bacteriochlorins, isobacteriochlorins), hematoporphyrin, benzoporphyrin, texaohyrins, chlorophylls, dyes, aminolevulinic acid (ALA), silicon phthalocyanine Pc 4, m- tetrahydroxyphenylchlorine (mTHPC), mono-L-aspartyl chlorine (Npe6), pyropheophosphides, purpurins, texaphyrins, phenothiaziniums, phthalocyanines, napthalocyanines, porphycenes, pheophorbides, merocyanine, phthalocyanine, chloroaluminum phthalocyanine, sulfonated aluminum phthalocyanine, ring-substituted cationic phthalocyanine, disulfonated or tetrasulfonated derivative, sulfonated aluminum naphthalocyanine, naphthalocyanine, tetracyanoethylene adduct, crystal violet, azure P chloride, benzophenothiazinium, benzophenothiazinium chloride (EtNBS), phenothiazine derivative, rose Bengal, toluidine blue derviatives, toluidine blue O (TBO), methylene blue (MB), new methylene blue N (NMMB), new methylene blue BB, new methylene blue FR, 1,9-dimethylmethylene blue chloride (DMMB), methylene blue derivatives, methylene green, methylene violet Bernthsen, methylene violet 3RAX, Nile blue, Nile blue derivatives, malachite green, Azure blue A, Azure blue B, Azure blue C, safranine O, neutral red, 5- ethylamino-9-diethylaminobenzo[a]phenothiazinium chloride, 5-ethylamino-9- diethylaminobenzo[a]phenoselenazinium chloride, thiopyronine, thionine, or combination thereof. Photosensitizers currently approved by the FDA for photodynamic therapy, such as Photofyrin (actually a mixture of porphyrins, including photoporphyrin, haematoporphyrin, hydroxyethyldeuteropophyrin); and verteporfin, a benzoporphyrin, can also be used in the compositions. In certain embodiments, the photosensitizers can contain metal cations. The metal ion present in the photosensitizer can be a diamagnetic metal. The metal ion present in the photosensitizer can be a diamagnetic metal. Suitable diamagnetic metals include, but are not limited to aluminum, copper, zinc, tin, silicon, germanium, lithium, magnesium, platinum, palladium, iridium, rudinium, ruthenium, rhenium, osmium, technetium, and combinations thereof. Suitable examples of metal-containing photosensitizers include, but are not limited to, zinc phthalocyanine, sulfonated aluminum phthalocyanine, and magnesium phthalocyanine, and zinc tetraphenyl porphyrin. In some examples, the photosensitizer is not covalently linked to the mesoporous material.

[0068] Selected Definitions

[0069] As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and / or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising”. The transitional terms / phrases (and any grammatical variations thereof) “comprising,” “comprises,” “comprise,” can be used interchangeably.

[0070] The phrases “consisting essentially of’ or “consists essentially of’ indicate that the claim encompasses embodiments containing the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claim.

[0071] The transitional term “comprising,” “comprises,” or “comprise” is inclusive or open- ended and does not exclude additional, unrecited elements or method steps. By contrast, the transitional phrase “consisting of’ excludes any element, step, or ingredient not specified in the claim. The phrases “consisting” or “consists essentially of’ indicate that the claim encompasses embodiments containing the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claim. Use of the term “comprising” contemplates other embodiments that “consist” or “consisting essentially of’ the recited component s).

[0072] The term “about” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured, z.e., the limitations of the measurement system. In the context of compositions containing amounts of ingredients where the term “about” is used, these compositions contain the stated amount of the ingredient with a variation (error range) of 0-10% around the value (X ± 10%). In other contexts, the term “about” is providing a variation (error range) of 0- 10% around a given value (X ± 10%). As is apparent, this variation represents a range that is up to 10% above or below a given value, for example, X ± 1%, X ± 2%, X ± 3%, X ± 4%, X ± 5%, X ± 6%, X ± 7%, X ± 8%, X ± 9%, or X ± 10%.

[0073] In the present disclosure, ranges are stated in shorthand to avoid having to set out at length and describe each and every value within the range. Any appropriate value within the range can be selected, where appropriate, as the upper value, lower value, or the terminus of the range. For example, a range of 0.1-1.0 represents the terminal values of 0.1 and 1.0, as well as the intermediate values of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and all intermediate ranges encompassed within 0.1-1.0, such as 0.2-0.5, 0.2-0.8, 0.7-1.0, etc. Values having at least two significant digits within a range are envisioned, for example, a range of 5-10 indicates all the values between 5.0 and 10.0 as well as between 5.00 and 10.00 including the terminal values. When ranges are used herein, combinations and subcombinations of ranges (e.g., subranges within the disclosed range) and specific embodiments therein are explicitly included.

[0074] By “reduces” is meant a negative alteration of at least 1%, 5%, 10%, 25%, 50%, 75%, or 100%.

[0075] By “increases” is meant as a positive alteration of at least 1%, 5%, 10%, 25%, 50%, 75%, or 100%.

[0076] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

[0077] As used herein, “photodynamic therapy” and “PDT” are used interchangeably to refer to a treatment that uses special drugs, called photosensitizing agents, along with light to kill cancer cells.

[0078] As used herein, “protein photosensitizer” refers to proteins that generate reactive oxygen species upon light irritation. These are useful for spatiotemporal protein inactivation and cell ablation.

[0079] “Chlorophyll” is a green pigment, present in all green plants and in cyanobacteria responsible for the absorption of light to provide energy for photosynthesis. Chlorophyll derivates include temoporfm and talaporfin, both photosensitizers. As used herein “tumor suppression” describes when a tumor is prohibited from developing. In some embodiments, tumor suppression can occur from a tumor suppression gene that is inactivated by a mutation.

[0080] As used herein, “HeLa cells” refer to an immortal human cell like that is durable and prolific line of cells used in research. They are easily shared and multiplied in labs, making them suitable for research.

[0081] The terms “treatment” or any grammatical variation thereof (e.g., treat, treating, etc.), as used herein, includes but is not limited to, the application or administration to a subject (or application or administration to a cell or tissue from a subject) with the purpose of slowing, stabilizing, curing, healing, alleviating, relieving, remedying, less worsening, ameliorating, or improving the disease or condition. The term “treating” refers to any indication of success in the treatment or amelioration of a pathology or condition, including any objective or subjective parameter such as abatement; remission; lessening of the rate of worsening; lessening severity of the disease; stabilization, diminishing of symptoms or making the pathology or condition more tolerable to the subject; or improving a subject’s physical or mental well-being.

[0082] The term “effective amount” or “therapeutically effective amount” refers to that amount of the photosensitizer or photosensitizing agent, or a composition comprising them, described herein that is sufficient to effect treatment of the cancer. The therapeutically effective amount may vary depending upon the intended application, the subject, and the cancer being treated, e.g., the weight and age of the subject, the severity of the cancer, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The specific dose will vary depending on the particular dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

[0083] “Pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic, and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions. “Subject” refers to an animal, such as a mammal, for example a human. The methods described herein can be useful in both pre-clinical human therapeutics and veterinary applications. In some embodiments, the subject is a mammal (such as an animal model of disease), and in some embodiments, the subject is human. Non-limiting examples of subjects include canine, porcine, rodent, feline, bovine, poultry, equine, human, and a non-human primate.

[0084] “Contacting a cell” is understood herein as providing an agent to a cell e.g., a cell to be treated in culture, ex vivo, or in an animal, such that the agent can interact with the cell (e.g., cell to be treated), potentially be taken up by the cell, and have an effect on the cell. The agent can be delivered to the cell directly (e.g., by addition of the agent to culture medium or by injection into the cell or tissue of interest), or by delivery to the organism by a topical or parenteral route of administration for delivery to the cell by vascular, lymphatic, or other means. One of ordinary skill in the art will readily understand that administration of the agent of the invention to a subject involves contacting the agent with a cell of the subject.

[0085] As used herein, “encodes” or “encoding” refers to a DNA and / or RNA sequence that can be processed to generate an RNA and / or polypeptide.

[0086] As used herein, “variants” of a protein refer to sequences that have one or more amino acid substitutions, deletions, additions, and / or insertions. In preferred embodiments, these substitutions, deletions, additions and / or insertions do not materially adversely affect the protein activity. Variants that retain one or more biological activities are within the scope of the present invention.

[0087] “Fragments” and its variants are also within the scope of proteins of the subject invention, so long as the fragment retains one or more biological properties. Preferably, the fragment is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the full-length protein.

[0088] Compositions

[0089] In one embodiment, the subject invention provides a pharmaceutical composition comprising a photosensitizing agent for PDT. In one embodiment, the photosensitizing agent for use in PDT comprises a water-soluble biopolymer and one or more organic photosensitizers (e.g., chlorophylls). In a further embodiment, the water-soluble biopolymer is a peptide and / or protein that can bind to the one or more organic photosensitizer, preferably, two to four organic photosensitizer, to form a complex. In a further embodiment, the organic photosensitizer is capable of absorbing visible light to emit fluorescence and generating active oxygen. Preferably, the organic photosensitizer is a tetrapyrrole-based compound.

[0090] In a preferred embodiment, the water-soluble biopolymer is WSCP. In a specific embodiment, the WSCP comprises an amino acid sequence of SEQ ID NO: 1, biologically- active fragments, variants thereof, or an amino acid sequence sharing at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 1.

[0091] In a preferred embodiment, the organic photosensitizer is chlorophyll.

[0092] In a specific embodiment, the photosensitizing agent for use in PDT is a WSCP and / or WSCP complex according to the subject invention, which comprises a water-soluble WSCP and one or more chlorophylls. In a specific embodiment, the photosensitizing agent is a tetrameric WSCP complex, which is highly soluble in water and exhibits extraordinary thermostability and astounding photostability. Advantageously, the tetrameric WSCP complex retains the ability as photosensitizers for converting ground-state oxygen (3O2) to single oxygen (' O2).

[0093] In certain embodiments, the composition of the subject invention may further comprise an organic photosensitizer selected from, for example, photofrin, Laserphyrin, protoporphyrin IX, Foscan, chlorins, uroporphyrin I, uroporphyrin III, heptacarboxylporphyrin I, heptacarboxylporphyrin III, hexacarboxylporphyrin I, hexacarboxylporphyrin III, pentacarboxylporphyrin I, pentacarboxylporphyrin III, coproporphyrin I, coproporphyrin III, isocoproporphyrin, harderoporphyrin, isoharderoporphyrin, hematoporphyrin, mesoporphyrin, etioporphyrin, pyrroporphyrin, deuteroporphyrin IX, pemptoporphyrin, and ATXs-10.

[0094] In certain embodiments, the composition of the subject invention may further comprise a photosensitizer selected from, for example, porphyrin and their derivatives, pyrrole, tetrapyrollic compound, expanded pyrrolic macrocycle and their derivatives, cyanine and their derivatives, flavin, organometallic species, nanoparticle, or combinations thereof.

[0095] Other representative examples of photosensitizer that may be included in the composition of the subject invention include, but are not limited to, green porphyrins, protoporphyrin, chlorins, tetrahydrochlorins (chlorins bacteriochlorins, isobacteriochlorins), hematoporphyrin, benzoporphyrin, texaohyrins, chlorophylls, dyes, aminolevulinic acid (ALA), silicon phthalocyanine Pc 4, m-tetrahydroxyphenylchlorine (mTHPC), mono-L- aspartyl chlorine (Npe6), pyropheophosphides, purpurins, texaphyrins, phenothiaziniums, phthalocyanines, napthalocyanines, porphycenes, pheophorbides, merocyanine, phthalocyanine, chloroaluminum phthalocyanine, sulfonated aluminum phthalocyanine, ring- substituted cationic phthalocyanine, disulfonated or tetrasulfonated derivative, sulfonated aluminum naphthalocyanine, naphthalocyanine, tetracyanoethylene adduct, crystal violet, azure P chloride, benzophenothiazinium, benzophenothiazinium chloride (EtNBS), phenothiazine derivative, rose Bengal, toluidine blue derviatives, toluidine blue O (TBO), methylene blue (MB), new methylene blue N (NMMB), new methylene blue BB, new methylene blue FR, 1,9-dimethylmethylene blue chloride (DMMB), methylene blue derivatives, methylene green, methylene violet Bemthsen, methylene violet 3RAX, Nile blue, Nile blue derivatives, malachite green, Azure blue A, Azure blue B, Azure blue C, safranine O, neutral red, 5-ethylamino-9-diethylaminobenzo[a]phenothiazinium chloride, 5- ethylamino-9-diethylaminobenzo[a]phenoselenazinium chloride, thiopyronine, thionine, or combination thereof. Photosensitizers currently approved by the FDA for photodynamic therapy, such as Photofyrin (actually a mixture of porphyrins, including photoporphyrin, haematoporphyrin, hydroxyethyldeuteropophyrin); and verteporfm, a benzoporphyrin, can also be used in the compositions.

[0096] In one embodiment, the composition of the subject invention further comprises a pharmaceutically acceptable carrier, adjuvant, and / or diluent. The carrier and / or diluent can generally be any suitable medium by which the desired purpose is achieved and that does not affect the photosensitizers’ capability to be directed to the desired target for the desired effect. Particularly, the carrier and / or diluent should not deteriorate the pharmacological potency of the active agent and the capability of the complex to be directed to a desired target within, or on, the animal body. Preferably, said carrier and / or diluent is / are selected from water, physiologically acceptable aqueous solutions containing salts and / or buffers and any other solution acceptable for administration to an animal. Such carriers and diluents are well known to a person skilled in this field and can be, for example, distilled water, de-ionized water, pure or ultrapure water, saline, phosphate-buffered saline (PBS), solutions containing usual buffers which are compatible with the other components of the drug targeting system etc.

[0097] In one embodiment, the pharmaceutical composition comprising compounds according to the invention, together with a conventional adjuvant, carrier, or diluent, may be placed into the form of solids including tablets, filled capsules, powder and pellet forms, and liquids such as aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same. The composition may further comprise conventional ingredients in conventional proportions, with or without additional active compounds.

[0098] In certain embodiments, the composition is in a powder form. The pharmaceutically accepted carrier is a finely divided solid that is in a mixture with the finely divided active compounds. In another embodiment, the composition is in a tablet form. The active component is mixed with the pharmaceutically accepted carrier having the necessary binding capacity in suitable proportions and compacted in desired shape and size. Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.

[0099] The effective amount of said pharmaceutical composition can be administered through, for example, oral, rectal, bronchial, nasal, topical, buccal, sub-lingual, transdermal, vaginal, intramuscular, intraperitoneal, intravenous, intra-arterial, intracerebral, interaocular administration or in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems such as semipermeable matrices of solid hydrophobic polymers containing the compound(s) of the invention. Administration may be also by way of other carriers or vehicles such as patches, micelles, liposomes, vesicles, implants (e.g., microimplants), synthetic polymers, microspheres, nanoparticles, and the like.

[0100] In one embodiment, the composition is formulated for parenteral administration (e.g., by injection). In addition, the composition may be presented in unit dose form in ampoules, pre-filled syringes, and small volume infusion or in multi-dose containers with or without an added preservative. The compositions may be in forms of suspensions, solutions, or emulsions in oily or aqueous vehicles. The composition may further contain formulation agents such as suspending, stabilizing and / or dispersing agents.

[0101] In one embodiment, the composition can be formulated in solutions or suspensions for parenteral, intradermal, or subcutaneous application, which can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine; propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0102] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the injectable composition should be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the requited particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are, for example, vacuum drying and freeze drying techniques.

[0103] In one embodiment, the composition may be formulated in an aqueous solution for oral administration. The composition may be dissolved in suitable solutions with added suitable colorants, flavors, stabilizing and thickening agents, artificial and natural sweeteners, and the like. In addition, the composition may further be dissolved in solution containing viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.

[0104] Oral compositions may include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder (such as microcrystalline cellulose, gelatin, a sugar, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose); an excipient (such as such as lactose, mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch, and dibasic calcium phosphate dehydrate); a disintegrating agent (such as alginic acid, Primogel, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate); a lubricant (such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulfate); a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0105] In certain embodiments, the composition is applied topically or systemically or via a combination of both. The composition may be formulated in the forms of lotion, cream, gel and the like.

[0106] In one embodiment, the composition can be applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form. Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or di chlorotetrafluoroethane, carbon dioxide, or other suitable gas.

[0107] The composition of the subjection invention may also be administered in a controlled release formulation such as a slow release or a fast release formulation. Such controlled release formulations of the combinations of this invention may be prepared using methods well known to those skilled in the art. The method of administration will be determined by the attendant physician or other person skilled in the art after an evaluation of the subject's condition and requirements.

[0108] In one embodiment, the pharmaceutical composition is provided in a unit dosage form, wherein the composition in desired form is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities such as packaged tablets, capsules, and powders in vials or ampoules. Moreover, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. In a preferred embodiment, tablet or capsule forms are for oral administration and liquid form are for intravenous administration and continuous infusion.

[0109] In one embodiment, dosage units containing the drug contain about 0.01 mg to 1000 mg, about 0.01 mg to 900 mg, about 0.01 mg to 800 mg, about 0.01 mg to 700 mg, about 0.01 mg to 600 mg, about 0.01 mg to 500 mg, about 0.05 mg to 500 mg, about 0.1 mg to 400 mg, about 0.1 mg to 300 mg, about 0.1 mg to 200 mg, about 0.1 mg to 100 mg, about 0.1 mg to 90 mg, about 0.1 mg to 80 mg, about 0.1 mg to 70 mg, about 0.1 mg to 60 mg, about 0.1 mg to 50 mg, about 0.1 mg to 40 mg, about 0.1 mg to 30 mg, about 0.1 mg to 20 mg, about 0.1 mg to 10 mg, about 0.5 mg to 50 mg, about 1 mg to 40 mg, about 1 mg to 20 mg, about 1 mg to 10 mg, or about 1 mg to 5 mg.

[0110] Therapeutic applications

[0111] PDT involves the administration of a photosensitizer or photosensitizing agent to an area of interest. The therapeutic effect of PDT is based on a phototoxic reaction: the photosensitizer or photosensitizing agent is taken up into the cells. Upon exposure of the area of interest to light of a suitable wavelength, the photosensitizer is excited from a ground state to an excited singlet state. It then undergoes intersystem crossing to a longer-lived excited triplet state. When the photosensitizer and an oxygen molecule are in proximity, an energy transfer can take place that allows the photosensitizer to relax to its ground singlet state, and create an excited singlet state oxygen molecule. Singlet oxygen is a very aggressive chemical species and will rapidly react with any nearby biomolecules. Ultimately, these reactions will kill cancer cells.

[0112] In one embodiment, the subject invention provides a method of PDT for treating cancer, the method comprising administering to a subject in need of such treatment an effective amount of a photosensitizer or photosensitizing agent of the subject invention or a pharmaceutical composition of the subject invention; and irradiating cancer with, or exposing the area in need of PDT to, an excitation light at a suitable wavelength.

[0113] In one embodiment, the wavelength for exciting the photosensitizer or the photosensitizing agent ranges, for example, from about 400 nm to about 900 nm, from about 450 nm to about 850 nm, from about 500 nm to about 800 nm, from about 550 nm to about 750 nm, from about 600 nm to about 700 nm, from about 600 nm to about 800 nm, from about 600 nm to about 900 nm, from about 400 nm to about 700 nm, from about 400 nm to about 600 nm, or from about 400 nm to about 500 nm. In a preferred embodiment, the wavelength for exciting the photosensitizer or the photosensitizing agent ranges from about 600 to about 700 nm. In a specific embodiment, the light is white light or red light.

[0114] In a specific embodiment, UV-vis spectra of the recombinant WSCP exhibits intense absorption band in the range of 350 - 480 nm and 600-700 nm with the maxima at 435 and 665 nm and photoluminescence (PL) spectra of the recombinant WSCP displayed a maximal emission peak at 684 and 735 nm (excited at 634 nm).

[0115] In certain embodiments, irradiating cancer, or the area in need of PDT, with a light having an irradiance or intensity of, for example, about 0.1 mW / cm2to about 1 W / cm2, about 0.5 mW / cm2to about 0.9 W / cm2, about 0.8 mW / cm2to about 0.8 W / cm2, about 1 mW / cm2to about 0.7 W / cm2, about 1 mW / cm2to about 0.6 W / cm2, about 1 mW / cm2to about 0.5 W / cm2, about 1 mW / cm2to about 0.4 W / cm2, about 1 mW / cm2to about 0.3 W / cm2, about 1 mW / cm2to about 0.25 W / cm2, about 2 mW / cm2to about 200 mW / cm2, about 5 mW / cm2to about 150 mW / cm2, about 10 mW / cm2to about 120 mW / cm2, about 5 mW / cm2to about 100 mW / cm2, about 10 mW / cm2to about 100 mW / cm2, about 10 mW / cm2to about 80 mW / cm2, about 10 mW / cm2to about 70 mW / cm2, about 10 mW / cm2to about 50 mW / cm2, about 10 mW / cm2to about 40 mW / cm2, about 10 mW / cm2to about 30 mW / cm2, about 10 mW / cm2to about 20 mW / cm2, about 5 mW / cm2to about 50 mW / cm2, about 5 mW / cm2to about 20 mW / cm2, about 5 mW / cm2to about 10 mW / cm2, about 1 mW / cm2to about 20 mW / cm2, about 1 mW / cm2to about 50 mW / cm2, about 1 mW / cm2to about 10 mW / cm2, or about 1.5 mW / cm2to about 12.5 mW / cm2. In a preferred embodiment, irradiating cancer, or the area in need of PDT, with a light having an irradiance or intensity of, for example, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10 mW / cm2.

[0116] In certain embodiments, the light is provided at a light dose of for example, about 0.1 mJ / cm2to about 20 J / cm2, about 1 mJ / cm2to about 15 J / cm2, about 10 mJ / cm2to about 10 J / cm2, about 20 mJ / cm2to about 10 J / cm2, about 50 mJ / cm2to about 10 J / cm2, about 100 mJ / cm2to about 10 J / cm2, about 200 mJ / cm2to about 10 J / cm2, about 300 mW / cm2to about 9 J / cm2, about 400 mJ / cm2to about 8 J / cm2, about 500 mJ / cm2to about 7 J / cm2, about 600 mJ / cm2to about 6 J / cm2, about 700 mJ / cm2to about 5 J / cm2, about 800 mJ / cm2to about 4 J / cm2, about 900 mJ / cm2to about 3 J / cm2, about 1 J / cm2to about 3 J / cm2, about 1 J / cm2to about 2 J / cm2, about 1 J / cm2to about 4 J / cm2, about 1 J / cm2to about 5 J / cm2, about 1 J / cm2to about 8 J / cm2, about 1 J / cm2to about 10 J / cm2, about 2 J / cm2to about 10 J / cm2, about 5 J / cm2to about 10 J / cm2, about 5 J / cm2to about 20 J / cm2, or about 10 J / cm2to about 20 J / cm2. In a preferred embodiment, the light is provided at a light dose of for example, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10 J / cm2.

[0117] In certain embodiments, irradiation to the light is carried out for a period of, for example, about 0.1 to about 240 minutes, about 0.5 to about 180 minutes, about 1 to about

[0118] 120 minutes, about 1 to about 80 minutes, about 1 to about 70 minutes, about 1 to about 60 minutes, about 1 to about 50 minutes, about 1 to about 40 minutes, about 1 to about 30 minutes, about 1 to about 20 minutes, about 1 to about 10 minutes, about 2 to about 10 minutes, about 2 to about 20 minutes, about 2 to about 30 minutes, about 2 to about 40 minutes, about 5 to about 40 minutes, about 5 to about 30 minutes, or about 5 to about 20 minutes. In certain embodiments, irradiation to the light is carried out for a period of, for example, about 1, 2, 5, 10, 15, 20, 25, 30, 35, or 40 minutes,

[0119] In some embodiments, the step of irradiation is carried out after a period of time after the administration of the photosensitizer or photosensitizing agent of the subject invention or the pharmaceutical composition of the subject invention, wherein the period of time is for example, about 0.1 to about 24 hours, about 0.2 to about 20 hours, about 0.3 to about 18 hours, about 0.5 to about 15 hours, about 1 to about 12 hours, about 2 to about 10 hours, about 2 to about 8 hours, about 2 to about 6 hours, about 1 to about 4 hours, about 1 to about 6 hours, about 1 to about 8 hours, about 4 to about 10 hours, or about 4 to about 12 hours.

[0120] In one embodiment, the subject invention provides a PDT for treating cancer, the PDT comprising administering to a subject in need of such treatment an effective amount of a photosensitizer or photosensitizing agent of the subject invention or a pharmaceutical composition of the subject invention; and irradiating cancer with, or exposing the area in need of PDT to, an excitation light at a suitable wavelength.

[0121] In one embodiment, the method of PDT comprises exposing the photosensitizer or photosensitizing agent of the subject invention to an excitation light at a suitable wavelength.

[0122] In one embodiment, the subject invention provides a method of PDT for treating cancer, the method comprising contacting cancer cells with an effective amount of a photosensitizer or photosensitizing agent of the subject invention or a pharmaceutical composition of the subject invention; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the photosensitizer or photosensitizing agent of the subject invention to an excitation light at a suitable wavelength.

[0123] In one embodiment, the subject invention provides a method of PDT for treating cancer, the method comprising administering to a subject in need of such treatment an effective amount of a WSCP complex or a pharmaceutical composition comprising the ESCP complex; and irradiating cancer with, or exposing the area in need of PDT to, an excitation light at a suitable wavelength.

[0124] In one embodiment, the subject invention provides a method of PDT for treating cancer, the method comprising contacting cancer cells with an effective amount of a WSCP complex or a pharmaceutical composition comprising the WSCP complex; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the WSCP complex to an excitation light at a suitable wavelength.

[0125] In a specific embodiment, the WSCP complex comprises WSCP and two or four chlorophylls. Advantageously, the WSCP complexes greatly stabilizes the unstable chlorophylls with retention of their ability as a photosensitizer to generate ROS upon light irradiation for PDT. Also, the WSCP complex is highly soluble in water and exhibits extraordinary thermostability and astounding photostability.

[0126] In a preferred embodiment, the WSCP comprises an amino acid sequence of SEQ ID NO: 1, biologically-active fragments, variants thereof, or an amino acid sequence sharing at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 1.

[0127] In one embodiment, the subject invention provides a method of PDT for treating cervical cancer, the method comprising administering to a subject in need of such treatment an effective amount of a WSCP complex or a pharmaceutical composition comprising the ESCP complex; and irradiating cancer with, or exposing the cancer area to, an excitation light at a suitable wavelength.

[0128] In one embodiment, the PDT method of the invention is used for treatment of cancer and comprises administering to a patient afflicted with a solid tumor a therapeutically effective amount of a WSCP complex according to the invention, and then irradiating the tumor site with strong light sources at 600-900 nm.

[0129] The WSCP complex or composition comprising WSCP complex of the present invention can be administered to the subject being treated by standard routes, including the local, oral, buccal, bronchial, ophthalmic, sub-lingual, nasal, topical, intratumoural, transdermal, intra-articular, parenteral (e.g., intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular), intracranial, intracerebral, intraspinal, intravaginal, intrauterine, or rectal route. Administration may be also by way of other carriers or vehicles such as patches, micelles, liposomes, vesicles, implants (e.g., microimplants), synthetic polymers, microspheres, nanoparticles, and the like. Depending on the condition being treated, one route may be preferred over others, which can be determined by those skilled in the art.

[0130] In certain embodiments, cancer cells include any cells derived from a tumor, neoplasm, cancer, precancer, cell line, malignancy, or any other source of cells that have the potential to expand and grow to an unlimited degree. Cancer cells may be derived from naturally occurring sources or may be artificially created. Cancer cells may also be capable of invasion into other tissues and metastasis. Cancer cells further encompass any malignant cells that have invaded other tissues and / or metastasized. One or more cancer cells in the context of an organism may also be called a cancer, tumor, neoplasm, growth, malignancy, or any other term used in the art to describe cells in a cancerous state.

[0131] Examples of cancers that could serve as sources of cancer cells include solid tumors such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma.

[0132] In certain embodiments, the cancer is selected from, for example, superficial and subcutaneous cancers such as warts, cervical cancer, skin cancer, thyroid cancer, and malignant brain tumor, especially several millimeter-deep subcutaneous cancer.

[0133] In certain embodiments, the cancer can be treated by PDT of the subject invention include, for example, solid tumors such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma.

[0134] In specific embodiments, the cancer treated by PDT of the subject invention is selected from, for example, cervical cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, and bone cancer.

[0135] In certain embodiments, the light source for irradiation with excitation light at a suitable wavelength may be a well-known one. For example, the light source with excitation light at a suitable wavelength may be a lamp or laser such as a semiconductor laser. In a preferred embodiment, the light source is a LED light, preferably a flash / light-type LED.

[0136] In one embodiment, the subject invention provides a method for inhibiting / reducing cancer cell growth via PDT, the method comprising contacting cancer cells with an effective amount of a WSCP complex or a pharmaceutical composition comprising the WSCP complex; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the WSCP complex to an excitation light at a suitable wavelength.

[0137] In one embodiment, the subject invention provides a method for inducing cancer cell death via PDT, the method comprising contacting cancer cells with an effective amount of a WSCP complex or a pharmaceutical composition comprising the WSCP complex; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the WSCP complex to an excitation light at a suitable wavelength.

[0138] In one embodiment, the subject invention discloses the use of the photosensitizers / photosensitizing agents, and compositions comprising them to kill endogenous tissue or cells. In certain embodiments, the tissue can be undesirable tissue that has arisen due to transformation, such as a tumor, cancer, or endometriosis; adipose tissue; plaques present in vascular tissue and over-proliferation such as those formed in restenosis; birthmarks and other vascular lesions of the skin; scars and adhesions; and irregularities in connective tissue or bone, such as bone spurs.

[0139] In some embodiments, the photosensitizers / photosensitizing agents, and compositions comprising them for PDT can be useful to cause photodynamic damage to cancer cells. Photodynamic damages to cancer cells include, but are not limited to, preventing or reducing the development of a cancer, reducing the symptoms of cancer, suppressing or inhibiting the growth of an established cancer, preventing metastasis and / or invasion of an existing cancer, promoting or inducing regression of the cancer, inhibiting or suppressing the proliferation of cancerous cells, reducing angiogenesis or increasing the amount of apoptotic cancer cells, thereby treating cancer.

[0140] In certain embodiments, the method of the subject invention comprises contacting a cell with an effective amount of the photosensitizers / photosensitizing agents, and / or compositions comprising them. One of skill in the art recognizes that an amount can be considered therapeutically effective even if the condition is not totally eradicated but improved partially.

[0141] In certain embodiments, the compositions can be injected directly into the target tissue, or can be administered systemically. More specifically, the compositions can be administered using any suitable method including intravenous (i.v.), intraperitoneal (i.p.), intramuscular (i.m.), intratumoral (i.t), intraarterial (i.a.), topically, and / or inhalation. Intravenous administration is particularly preferred for solid tumors, while i.p. administration is preferred for pancreatic, liver, and gastric tumors. Advantageously, even when administered systemically, the compositions preferentially accumulate in the cancerous tissue, and preferably actively integrate in the cancerous tissue, as opposed to surrounding healthy tissue.

[0142] In certain embodiments, the methods also comprise the application of external radiation for the purpose of exciting the photosensitizers / photosensitizing agents. The rate and time the cancerous cells are irradiated may depend on the results required. For example, the cells can be irradiated at an effective intensity and time to cause permeabilization of the endothelial lining of the cancerous cells, i.e., increase in the Enhanced Permeabilization and Retention (EPR) effect without causing significant occlusion and / or collapse to tumor blood vessels. The cancerous cells can be irradiated at an effective intensity and time to cause therapeutic injury resulting in the reduction of at least one of the surface area, the depth, and the amount of the tissue affected by the cancerous condition. The irradiation regime may also be dependent on the compositions, the maximum safe dose of radiation that can be tolerated by the patient, or the targeted cell or material.

[0143] In some embodiments, irradiation can be any form of excitation radiation, including high-energy particles and radiation from all regions of the electromagnetic spectrum; ultrasound, electric fields and magnetic fields.

[0144] In one embodiment, the subject invention provides a method for photodynamically damaging cancer cells, the method comprising contacting the cancer cells with an effective amount of a photosensitizer of the subject invention or a pharmaceutical composition of the subject invention; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the photosensitizer to an excitation light at a suitable wavelength.

[0145] In one embodiment, the subject invention provides a method for photodynamically damaging cancer cells, the method comprising contacting the cancer cells with an effective amount of a WSCP complex or a pharmaceutical composition comprising the WSCP complex; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the WSCP complex to an excitation light at a suitable wavelength.

[0146] In one embodiment, the subject invention provides a method for inhibiting the proliferation of cancer cells, the method comprising contacting the cancer cells with an effective amount of a photosensitizer of the subject invention or a pharmaceutical composition of the subject invention; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the photosensitizer to an excitation light at a suitable wavelength.

[0147] In one embodiment, the subject invention provides a method for inhibiting the proliferation of cancer cells, the method comprising contacting the cancer cells with an effective amount of a WSCP complex or a pharmaceutical composition comprising the WSCP complex; and irradiating the cancer cells with an excitation light at a suitable wavelength, or exposing the WSCP complex to an excitation light at a suitable wavelength.

[0148] In specific embodiments, contacting cells, e.g., cancer cells, in vitro, with an effective amount of a WSCP complex or a pharmaceutical composition of the subject invention may comprise incubating the cancer cells with an effective amount of a WSCP complex or a pharmaceutical composition of the subject invention, or delivering an effective amount of a WSCP complex or a pharmaceutical composition directly into the cancer cells.

[0149] In certain embodiments, incubating the cancer cells with the WSCP complex or the composition of the subject invention is carried out for a period of, for example, at least 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 100 minutes, 120 minutes, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, 6.5 hours, 7 hours, 7.5 hours, 8 hours, 8.5 hours, 9 hours, 9.5 hours, 10 hours, 11 hours, 12 hours, 13 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 27 hours, 30 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, or 96 hours, or any period of time in between.

[0150] In certain embodiment, the methods of the subject invention may comprise a step of determining or measuring the uptake of the WSCP complex or WSCP in the cancer cells. In certain embodiments, the methods of the subject invention may further comprise a step of determining the size of the tumor prior to and / or after the exposure to light.

[0151] By way of illustration and not limitation, the following non-limiting exemplary embodiments are offered:

[0152] Embodiment 1. A method of photodynamic therapy (PDT) for treating cancer comprising administering to a subject in need of such therapy an effective amount of a water- soluble chlorophyll protein (WSCP) complex and irradiating cancer by exposing the WSCP complex to an excitation light.

[0153] Embodiment 2. The method of Embodiment 1, wherein the WSCP complex comprises a WSCP and 2-4 chlorophylls.

[0154] Embodiment s. The method of Embodiment 1, wherein the WSCP complex serves as a stable photosensitizer to generate reactive oxygen species for inducing cell death.

[0155] Embodiment 4. The method of Embodiment 2, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1, a biologically-active fragment thereof, a variant thereof, or an amino acid sequence sharing at least 95% identity with SEQ ID NO: 1.

[0156] Embodiment s. The method of Embodiment 2, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

[0157] Embodiment 6. The method of Embodiment 1, wherein the cancer is selected from fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma.

[0158] Embodiment 7. The method of Embodiment 1, wherein the cancer is selected from cervical cancer, lung cancer, ovarian cancer, liver cancer, and breast cancer.

[0159] Embodiment 8. The method of Embodiment 1, wherein the excitation light has a wavelength of about 600 nm to 900 nm.

[0160] Embodiment 9. The method of Embodiment 8, wherein the excitation light has a wavelength of about 600 nm to 700 nm.

[0161] Embodiment 10. The method of Embodiment 1, wherein the WSCP complex is administered intravenously, intraperitoneally, intramuscularly, intratumorally, intraarterially, topically, or orally.

[0162] Embodiment 11. A pharmaceutical composition for PDT comprising a water- soluble chlorophyll protein (WSCP) complex, wherein the WSCP complex comprises a WSCP and 2-4 chlorophylls.

[0163] Embodiment 12. The pharmaceutical composition of Embodiment 11, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1, a biologically-active fragment thereof, a variant thereof, or an amino acid sequence sharing at least 95% identity with SEQ ID NO: 1.

[0164] Embodiment 13. The pharmaceutical composition of Embodiment 11, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

[0165] Embodiment 14. A method for photodynamically damaging cancer cells, the method comprising contacting the cancer cells with the pharmaceutical composition of Embodiment 12 and irradiating the cancer cells with an excitation light.

[0166] Embodiment 15. The method of Embodiment 14, wherein the excitation light has a wavelength of about 600 nm to 700 nm.

[0167] Embodiment 16. The method of Embodiment 14, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1, a biologically-active fragment thereof, a variant thereof, or an amino acid sequence sharing at least 95% identity with SEQ ID NO: 1. Embodiment 17. The method of Embodiment 14, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

[0168] Embodiment 18. The method of Embodiment 14, wherein the cancer cells are selected from fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma.

[0169] Embodiment 19. A method for inhibiting the proliferation of cancer cells, the method comprising contacting the cancer cells with an effective amount of a water-soluble chlorophyll protein (WSCP) complex comprising a WSCP and 2-4 chlorophylls; and irradiating the cancer cells with an excitation light having a wavelength of about 600-900 nm.

[0170] Embodiment 20. The method of Embodiment 19, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

[0171] EXAMPLES

[0172] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

[0173] Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

[0174] Materials and methods Materials

[0175] All reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, USA), Thermo Fisher Scientific (Waltham, Massachusetts, USA), Gibco (Grand Island, New York, USA), Energy Chemical, and Beyotime Institute of Biotechnology (Haimen, Jiangsu, China).

[0176] Cell Lines

[0177] The HeLa cells, A549 cells, SKOV3 cells, Hep G2 cells, 4T1 cells, and B16F10 cells were obtained from the American Type Culture Collection (ATCC). L02 cells were gifts from Prof. Ying CHAU’s lab, HKUST. The HeLa cells, SKOV3 cells, Hep G2 cells, L02 cells, and B16F10 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Invitrogen) with 10% FBS, 1% penicillin / streptomycin. 4T1 cells and A549 cells were cultured in Roswell Park Memorial Institute 1640 (Gibco, Invitrogen) medium with 10% FBS (Gibco, Invitrogen), 1% penicillin / streptomycin (Gibco, Invitrogen). All cells were cultured in a humidified atmosphere containing 5% CO2 at 37 °C.

[0178] Bacteria

[0179] Gram-positive Staphylococcus aureus (ATCC 25923) and Gram-negative Escherichia coli K12 were used for the antibacterial effect evaluation. E. coli strain BL21 (DE3) harboring PET22b:WSCP was used for expression of the WSCP.

[0180] Animals

[0181] All animal studies were conducted under the guidelines set by The Government of the Hong Kong Special Administrative Region Committee Department of Health, and the overall project protocols were approved by the Animal Ethic Committee, VPRDO, The Hong Kong University of Science and Technology (HKUST). Female C57BL / 6J mice (5~6-week-old) were purchased from the Laboratory Animal Facility (CWB) of HKUST. Mice were housed in a temperature controlled (22 °C) room with 12 h dark-light cycles and 40-70% humidity. For construction of tumor-bearing mice, 100 pL of free FBS medium with 1 x 106B16F10 cells was injected into the right flank of 5 - 6 weeks old C57BL / 6J female mice. The size of the transplanted tumor xenograft was measured until its long diameter was around 60 mm3. Mice were randomly assigned to five groups (four mice per group): control (treated with 100 pL PBS via intratumoral injection), light irradiation alone (treated with 100 pL PBS via intratumoral injection and 152 mW / cm2660 nm light irradiation for 5 min at 4 h post injection), WSCP alone (treated with 30 mg / kg WSCP via intratumoral injection), and two experiment groups (treated with 30 mg / kg WSCP via intratumoral injection or intravenous injection respectively, and 152 mW / cm2660 nm light irradiation for 5 min at 4 h post injection). All treatments were performed at day 1, 3, 6, 9 and 12. The body weight and tumor volume were recorded every 3 days for 14 days. The tumor volume was calculated by using the following formula: tumor volume (mm3) = 7t / 6 x (length) x (width)2. After treatments for 14 days, all mice were euthanized and weighted. Tumors and major organs of mice (heart, liver, spleen, lung, kidney, thymus) were collected and weighted.

[0182] Instruments

[0183] Ultraviolet-visible (UV-Vis) absorbance was detected by PerkinElmer Lambda 365 Spectrophotometer. Fluorescence spectra were recorded with Edinburgh Instrument FS5 Fluorescence Spectrometer. For photothermal performance analysis, the sample was irradiated with 660 nm red light (1 W / cm2) by using PSU-III-LED light (Honkok Technology), temperature and infrared thermal images were recorded and captured by FLIR C3 thermal camera (Teledyne Technologies). For in vitro phototherapy, cells and bacteria were irradiated by using cellular photocytotoxicity irradiators (Shenzhen PURI Materials Technologies). Cells and bacteria viabilities were measured by FlexStation Multi-model microplate reader, and obtained data was proceeded and analyzed by using Graph Pad Prism 9 software. Flow cytometric analysis was performed on BS Aria III flow cytometer and analyzed through FlowJo software vlO. Confocal images were obtained by using Zeiss LSM 980 confocal microscope with AiryScan2 and proceeded with ZEN 2009 software. For in vivo anticancer phototherapy, tumor of mice was irradiated upon 660 nm red light (152 mW / cm2) by using Fiber Coupled Laser System (Beijing Blueprint Electronic Technology). Photos of wound healing assay and organ tissue slices were captured by Nikon Ts2 Eclipse light microscope.

[0184] Expression and Purification of Recombinant WSCP in E. coli.

[0185] The recombinant WSCP was produced in E. coli strain BL21 (DE3) harbouring PET22b: WSCP. Expression culture in LB containing ampicillin (100 «g / mL) was inoculated at 37 °C, 220 rpm and grown until OD 600 reached 0.6 - 0.8. Protein expression was induced by adding isopropyl P-D-l -thiogalactopyranoside (IPTG) (300 «M) at 37 °C. After 4 h, cell pellet was harvested by centrifugation.

[0186] To assembly WSCP with chlorophyll, excess amount of spinach extract was added to cell pellet in lysis buffer (300 mM NaCl, 100 mM Tris-HCl, 0.1 mM phenylmethyl sulfonyl fluoride (PMSF), pH 7.5). The mixture was sonicated to break cells and separate spinach extract. The homogenized lysate was centrifuged (18000 rpm, 45 min, 4 °C) to collect supernatant as a transparent green solution.

[0187] The reconstituted WSCP was purified using Ni-NTA chromatography, involving wash buffer (300 mM NaCl, 100 mM Tris, 50 mM imidazole, pH 7.5, 8 CV) and elution buffer (300 mM NaCl, 100 mM Tris, 500 mM imidazole, pH 7.5, 3 CV). The purified protein was dialyzed against Milli-Q water (4 L * 5), concentrated then stored at -80 °C after flashfreezing by liquid nitrogen. The protein purity was assessed using SDS-PAGE.

[0188] The amino acid sequence of WSCP (SEQ ID NO: 1):

[0189] INDEEP VKDTNGNPLKIETRYFIQPASDNNGGGL VP ANVDLSHLCPLGI VRTSLPYQPGLPVTISTPSSSEGNDVLTNTNIATFDAPIWPCPSSKTWTV DSSSEEKYIITGGDPKSGESFFRIEKYGNGKNTYKLVRYDNGEGKSVGS TKSLWGPALVLNDDDDSDENAFPIKFREVDT

[0190] Evaluation of dark toxicity of the recombinant WSCP on HeLa cells

[0191] The HeLa cells were used as model cells for evaluation of the dark toxicity of the recombinant WSCP. The cells were cultured in a 96-well plate at a density of 0.8 x 104 cells / well at 37°C with 5% CO2 humidified atmosphere for 24 h. Subsequently, the cultured medium was removed, and the cells were incubated with fresh medium containing the recombinant WSCP with different concentrations for another 48 h. Subsequently, 10 pL of 3- (4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) (5 mg / mL) was added to each well and the cells were incubated for at 37°C with 5% CO2 humidified atmosphere for 4 h. After removal of medium, 100 pL DMSO was added to each well to dissolve the precipitated formazan. Finally, the absorption of each well at 490 nm was measured. Data were expressed as the mean ± SD with three independent experiments.

[0192] Singlet Oxygen Generation Measurement

[0193] The singlet oxygen indicator 9, 10-anthracenediyl-bis(methylene)dimalonic acid (ABDA) was employed to measure the singlet oxygen generation of the recombinant WSCP and two commercial standard photosensitizers, Rose Bengal (RB) and Ce6 upon light irradiation. The absorbance of each sample (c = blO'4M) was firstly set as blank. Then to each sample was added ABDA (c = 2* 10'4M) in a dark room, and UV absorbance of samples were measured at once by PerkinElmer Lambda 365 Spectrophotometer and the absorbance of ABDA at 378 nm was recorded as Ao. Sample mixture was then irradiated upon white light (1 mW / cm2) or 660 nm red light (7 mW / cm2) at intervals of 30 seconds until 2 minutes. The UV absorption of ABDA at 378 nm (A) was recorded at various irradiation times (30 s, 60 s, 120 s) to obtain the decay rate of photosensitizing process. The absorbance change of ABDA alone was also monitored as control. The singlet oxygen generation efficiencies ( ROS) of photosensitizers upon light irradiation were measured and calculated by a modified method according to Liu’s report.50And the singlet oxygen generation efficiency (OROS) was defined as the ABDA decomposition slope of ln(Ao / A), where A0 and A are the absorbance of ABDA at 378 nm before and after light irradiation.

[0194] Photothermal Performance Analysis, visualization and photothermal stability of recombinant WSCP

[0195] The photothermal performance of the recombinant WSCP was investigated in 1.5 ml tube charged of different concentration of the recombinant WSCP (1 mg / mL, 2 mg / mL, 3 mg / mL) in H2O upon 660 nm red light (0.8 W / cm2) irradiation for 10 min. The photothermal stability of the recombinant WSCP was evaluated by 660 nm red light (0.8 W / cm2) irradiation for four on / off cycles. The temperature and Infrared thermal images of WSCP were recorded at various irradiation times to investigate the photothermal effect of the recombinant WSCP.

[0196] For visualization of the photothermal conversion performance of the recombinant WSCP, infrared thermal images of recombinant WSCP (2 mg / mL) in H2O were captured by infrared thermal images camera.

[0197] The photothermal stability of the recombinant WSCP (3 mg / mL) was evaluated by 660 nm red light (0.8 W / cm2) irradiation for four on / off cycles. 20 min per cycle (10 min light on and 10 min light off). Temperatures of samples were recorded every minute

[0198] Photothermal Conversion Efficiency Calculation

[0199] The photothermal conversion efficiency of the recombinant WSCP was measured according to the reported method2,3: h is the heat transfer coefficient; .s is the surface area of the container. QDIS represents heat dissipated from the laser mediated by the solvent and container. I is the laser power and A is the absorbance at 660 nm. m is the mass of the solution containing the photoactive material, C is the specific heat capacity of the solution (Cwater = 4.2 J / (g °C), and TS is the associated time constant. t = — Tsln(0)

[0200] 0 is a dimensionless parameter, known as the driving force temperature g > T1— T1surr

[0201] 1max1surr

[0202] Tmax and Tsurr are the maximum steady state temperature and the environmental temperature, respectively.

[0203] According to above reported method, the photothermal conversion efficiency of the recombinant WSCP upon 660 nm red light is 16.4%.

[0204] Long-term stability evaluations of free chlorophylls (Chis) and the recombinant WSCP at ambient.

[0205] The recombinant WSCP (2 mg / mL in H2O), free chlorophylls (2 mg / mL) in H2O and free chlorophylls (2 mg / mL) in MeOH were stored in 1.5 mL tube and placed upon normal room light at ambient temperature for 28 days, respectively. Status of samples were recorded by photography every day.

[0206] In Vitro Anticancer Phototherapy (cell viability)

[0207] For in vitro cytotoxicity evaluation, the cells were cultured in a 96-well plate at a density of 0.8 x 104cells / well at 37 °C with 5% CO2 humidified atmosphere for 24 h. Subsequently, the cultured medium was removed, and the cells were incubated with fresh medium containing the recombinant WSCP with different concentrations for another 24 h, and then cells were exposed with 660 nm light (63.3 mW / cm2) for 30 min. For non-irradiated groups the cells were stored in the dark for 30 min. After different treatments, the cells were incubated at 37 °C with 5% CO2 humidified atmosphere for 24 h. Subsequently, 10 u of 3- (4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) (5 mg / mL) was added to each well and the cells were incubated at 37°C with 5% CO2 humidified atmosphere for 4 h. After removal of the medium, 100 / L DMSO was added to each well to dissolve the precipitated formazan. Finally, the absorption of each well at 490 nm was measured by FlexStation Multi-model microplate reader. Data was processed and analyzed by using Graph Pad Prism 9 software.

[0208] The HeLa cells were used as model cells for investigation of effects of different irradiation time (5, 15, 30 min) of 660 nm red light (63.3 mW / cm2) on phototoxicity of the recombinant WSCP in vitro. Experiment procedure was followed above general procedure.

[0209] The HeLa cells were used as model cells for investigation of effects of 660 nm red light irradiation (30 min) upon light with different light power density (7.0, 20.6, 63.3 mW / cm2) on phototoxicity of the recombinant WSCP in vitro. Experiment procedure was followed above general procedure.

[0210] Cell viabilities of different cell lines after treatments with the WSCP phototherapy were investigated according to above general procedure.

[0211] Colony Formation

[0212] To evaluate the photo-induced anti-proliferation effect of WSCP, colony formation assay was performed. The cells were seeded in 6-well plates at a density of 1 x 103cells / well at 37 °C with 5% CO2 humidified atmosphere for 24 h. Subsequently, the cultured medium was removed, and the cells were incubated with fresh medium containing the recombinant WSCP with different concentrations for another 24 h, and then the cells were exposed with 660 nm light (31.8 mW / cm2, 15 min). For non-irradiated groups, the cells were stored in the dark. After treatment, the cells were incubated for another overnight and then washed with PBS. The cells were cultured for 14 days to form colonies and medium was changed every 3 days. After colony formation, the colonies were washed with PBS, fixed with 4% paraformaldehyde (PF A) for 10 min, and then stained with 0.2% crystal violet solution in 10% ethanol for 20 min before photo taking by using Nikon Eclipse Ts2 light microscope.

[0213] Wound Healing Assay

[0214] For wound healing assay, the cells were seeded in 6-well plates at a density of 1 x 106cells / well at 37 °C with 5% CO2 humidified atmosphere for 24 h. After creating a straight scratch with a sterile plastic tip, the cells were incubated with fresh medium with or without the recombinant WSCP (25 pg / mL) for another 24 h. Subsequently, the cells were exposed with 660 nm light (31.8 mW / cm2, 15 min). For non-irradiated groups, the cells were stored in the dark for 15 min. After treatments, the cells were incubated for 24 h and then washed with PBS. Finally, the cells were fixed with 4% paraformaldehyde (PFA) for 10 min, and then stained with 0.2% crystal violet solution in 10% ethanol for 20 min before photo taking. Images were obtained using Nikon Eclipse Ts2 light microscope.

[0215] Verification of Photodynamic Effect of the Recombinant WSCP

[0216] The HeLa cells were cultured in a 96-well plate at a density of 0.8 x io4cells / well at 37°C with 5% CO2 humidified atmosphere for 24 h. Subsequently, the cultured medium was removed, and the cells were incubated with 100 pL fresh medium containing N-acetyl-L- cysteine (NAC) (5 mM) the reactive oxygen species (ROS) scavenger for 2 h, and then the medium was removed, and the cells were added fresh medium containing both of NAC (5 mM) and the recombinant WSCP with different concentrations and incubated for another 24 h. Subsequently, cells were exposed with 660 nm light (63.3 mW / cm2) for 30 min. For nonirradiated groups, the cells were stored in the dark for 30 min. After different treatments, the cells were incubated at 37°C with 5% CO2humidified atmosphere for 24 h. Subsequently, 10 pL of 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) (5 mg / mL) was added to each well and the cells were incubated for at 37°C with 5% CO2 humidified atmosphere for 4 h. After removal of medium, 100 pL DMSO was added to each well to dissolve the precipitated formazan. Finally, the absorption of each well at 490 nm was measured.

[0217] Intracellular ROS Measurement

[0218] To evaluate cellular ROS generation of the recombinant WSCP, we utilized inverted confocal microscopy and flow cytometric analysis with 2’, 7’-dichlorofluorescin diacetate (DCF -DA) as an indicator to probe the intracellular reactive oxidative species generated. The DCF-DA was excited at 488 nm and the emission was collected at 500 - 530 nm. No background fluorescence of cells was detected under the setting condition.

[0219] For flow cytometry, the HeLa cells were seeded in 6-well plates at a density of 1 x 106cells / well. After different treatments, the cells were incubated with DCF-DA (5 pM) for 15 min before cell collection and analyzed by BD Aria III flow cytometer through FlowJo software vlO. From each sample, 1 x 104cells were counted. For confocal microscopy, the cells were seeded in confocal dishes at a density of 1 x 106cells / dish and incubated with WSCP (150pg / mL) for different time. Subsequently, after light irradiation, the cells were incubated with DCF-DA (5 pM) for 15 min. Then, the cells were washed with fresh medium before confocal analysis. Confocal images were obtained by using Zeiss LSM 980 confocal microscope with AiryScan2 and analyzed by ZEN 2009 software.

[0220] Intracellular Uptake Measurement

[0221] To evaluate the cellular uptake of the recombinant WSCP, Inverted confocal microscopy was utilized and flow cytometric analysis was performed. No background fluorescence of cells was detected under the setting condition.

[0222] For flow cytometry, cells were seeded in 6-well plates at a density of 1 x 106cells / well and incubated with WSCP for different incubated time. The cells were washed with PBS and then collected in tubes, and intracellular WSCP was detected by using APC-Cy7 channel through BD Aria III flow cytometer. From each sample, 1 x 104cells were counted.

[0223] For confocal microscopy, cells were seeded in confocal dishes (containing a coverslip for cells adhesion) at a density of 1 x io6cells / dish and then the cells incubated with WSCP for different incubated time. After washing with PBS, the cells were loaded with CellMask Green Plasma Membrane Stain for 15 minutes at room temperature to stain the cell membrane and then the cells were washed with PBS again and fixed by using 4% paraformaldehyde for 10 min. Finally, after washing with PBS twice times, the coverslip was mounted with ProLong Gold Anti -Fade containing 4',6-diamidino-2-phenylindole (DAPI) to stain the nucleus before confocal analysis. Confocal images of cells were obtained by using Zeiss LSM 980 confocal microscope with AiryScan2 and analysed by ZEN 2009 software. The WSCP was excited at 647 nm and the emission was recorded at 680-800 nm. CellMask Green Plasma Membrane Stain was excited at 488 nm and the emission was recorded at 500- 570 nm. DAPI was excited at 356 nm and the emission was recorded at 400-500 nm.

[0224] In Vivo Anticancer PDT

[0225] All animal experiments were performed in compliance with institutional animal care guidelines and according to committee-approved protocols. For construction of tumorbearing mice, 100 L of free FBS medium with 1 x 106B16F10 cells was injected into the right flank of 5-6 weeks old C57BL / 6J female mice. The size of the transplanted tumor xenograft was measured until its long diameter was around 60 mm3. Mice were randomly assigned to five groups (four mice per group): control (treated with 100 / L PBS via intratumoral injection), light irradiation alone (treated with 100 / L PBS via intratumoral injection and 152 mW / cm2660 nm light irradiation for 5 min at 4 h post injection), WSCP alone (treated with 30 mg / kg WSCP via intratumoral injection), and two experiment groups (treated with 30 mg / kg WSCP via intratumoral injection or intravenous injection respectively, and 152 mW / cm2660 nm light irradiation for 5 min at 4 h post injection). All treatments were performed at day 1, 3, 6, 9 and 12. The body weight and tumor volume were recorded every 3 days for 14 days. The tumor volume was calculated by using the following formula: tumor volume (mm3) = 7t / 6 x (length) x(width)2. After treatment for 14 days, all mice were euthanized and weighted. Tumors and major organs of mice (heart, liver, spleen, lung, kidney) were collected and weighted.

[0226] Hematoxylin and Eosin (H&E) staining

[0227] For histological analysis, major organs (including heart, liver, spleen, lung, kidney) and tumor tissues were harvested from killed mice on the 15thday post-treatment of different treatment conditions and fixed in 4 % paraformaldehyde. The samples were then dried and embedded in paraffin. Before H&E staining, tissue sections were dewaxed in xylene, rehydrated by gradient ethanol, washed with distilled water, and then stained with hematoxylin and eosin (H&E). After staining, the slices were dehydrated with increasing concentrations of ethanol and xylene. The morphological images of the tissues were captured using a light microscope.

[0228] Observation of the Recombinant WSCP Through Confocal Microscope.

[0229] For verification of the hypothesis of using confocal microscope to detect the intracellular WSCP, the HeLa cells were used as models for preliminary attempts. The HeLa cells were seeded in confocal dishes at a density of 1 x io6cells / dish and incubated at 37 °C with 5% CO2 humidified atmosphere for 24 h. After removal of the medium, the cells were added free medium with WSCP (150pg / mL) and observed through confocal microscope immediately. The recombinant WSCP was excited at 647 nm and the emission was collected at 680 - 800 nm. (With the time going upon the irradiation during the observation, cell morphology would change, and cell would be killed upon the irradiation by confocal instrument.) Observation of Unfixed HeLa Cells with Intracellular the Recombinant WSCP through Confocal Microscope

[0230] The HeLa cells were seeded in confocal dishes (containing a coverslip for cells adhesion) at a density of 1 x 106cells / dish and then the cells incubated with or without WSCP (150pg / mL) for different incubated time. After washing with PBS, the cells were loaded with or without CellMask Green Plasma Membrane Stain for 15 minutes at room temperature to stain the cell membrane and then then cells were washed with PBS again, and then the coverslip was mounted with ProLong Gold Anti-Fade containing 4',6-diamidino-2- phenylindole (DAPI) to stain the nucleus before confocal analysis without any cell fixation. For the group that staining membrane alone was used directly after washing with PBS without mounting with DAPI. Confocal images of cells were obtained by using Zeiss LSM 980 confocal microscope with AiryScan2 and analyzed by ZEN 2009 software. The recombinant WSCP was excited at 647 nm and the emission was collected at 680 - 800 nm. CellMask Green Plasma Membrane Stain was excited at 488 nm and emission was collected at 500 - 570 nm. DAPI was excited at 356 nm and emission was collected at 400 - 500 nm.

[0231] Statistics and Reproducibility

[0232] All data were expressed as the mean ± SD with at least three independent experiments. Graph Pad Prism 9 was used for one-way analysis of variance (ANOVA) to determine the difference between groups and followed by the Bonferroni test to compare all pairs of columns. ZEN 2009 software was used for confocal image analysis.

[0233] EXAMPLE 1— PHOTOPHYSICAL PROPERTIES OF WSCP

[0234] In PDT, an ideal photosensitizer can be excited at 650-900 nm (the therapeutic window), which cause less damage to skin and have a deeper penetration into tissues. WSCP absorbs light at the range of 350 - 480 nm and 600-700 nm,47which latter40could be used for PDT. UV-vis spectra of the recombinant WSCP (FIG. 1A) exhibited intense absorption band in the range of 350 - 480 nm and 600-700 nm with the maxima at 435 and 665 nm and photoluminescence (PL) spectra of the recombinant WSCP displayed a maximal emission peak at 684 and 735 nm (excited at 634 nm). The absorbance at 665 nm wavelength enables WSCP to be used as photosensitizers of PDT for cancers in deep tissues,49which is expected to outperform the traditional photosensitizers with low tissue penetrability. EXAMPLE 2— SINGLET OXYGEN GENERATION BY WSCP

[0235] The singlet oxygen generation is key to the therapeutic efficacy of most photosensitizers for PDT. WSCP was able to generate singlet oxygen from molecular oxygen upon irradiation with red light. To confirm the similar ability of recombinant WSCP for singlet oxygen generation, 9,10-anthracenediyl-bis(methylene) dimalonic acid (ABDA) was used as the trapping agent of singlet oxygen to investigate conversion of ground-state oxygen to singlet oxygen: absorbance decrease of ABDA indicated the singlet oxygen generation. The efficiency of singlet oxygen generation was compared with two commercial photosensitizers (Rose Bengal and Ce6). As shown in FIG. IB, the absorbance of ABDA alone did not change upon light irradiation (white light or 660 nm red light), suggesting no generation of singlet oxygen in the absent of photosensitizers. By contrast, the light absorbance of ABDA decreased significantly from 100% in 2 min after duration irradiation by white light (1 mW / cm2) in the present of Rose Bengal (46%) , Ce6 (86%) or recombinant WSCP (38%), respectively; and the absorbance of ABDA with the precence of WSCP could even drop to 6% after treatment with 660 nm red light (7 mW / cm2) irradiation for 2 min while that of ABDA with Ce6 could only achieve to 76% under the same condition. Noteworthy, WSCP demonstrated a significantly higher efficiency ROS [* 10’3S'1]50(8.2 upon white light irradiation; 24.1 upon red light irradiation.) of singlet oxygen generation than that of Rose Bengal (6.44 upon white light irradiation) and Ce6 (1.3 upon white light irradiation; 2.3 upon red light irradiation) under either white light or red light irradiation within the same irradiation time (FIG. 5 & Table 1). The astonishing efficiency of singlet oxygen generation at 660 nm red light irradiation renders WSCP advantageous to the possible PDT application for cancer treatment.

[0236] Table 1. Singlet oxygen generation efficiencies of different photosensitizers upon light irradiation

[0237] EXAMPLE 3— PHOTOTHERMAL PROPERTY Since the light irradiation usually results in temperature elevation, the photothermal effect of the recombinant WSCP was evaluated. The photothermal effect of WSCP upon irradiation could be easily visualized via infrared thermal imaging (FIG. 1C): the color of the WSCP solution was changing from blue (low temperature) to red (high temperature) under light irradiation over time, which suggested that the light irradiation of WSCP gave rise to the temperature elevation. To further quantify this effect, the temperature was measured (FIG. ID). Under 660 nm red light (0.8 W / cm2) irradiation, the temperature of the recombinant WSCP in water rose significantly to 40-50 °C from ambient temperatue with time while pure water showed negligible change of temperature and remained at around 29 to 30 °C. The photothermal effect was positively correlated to the concentration: temperature of 3 mg / mL WSCP could rise to nearly 50 °C upon light irradiation while WSCP at concentrations of 1 mg / mL could only increase to 40 °C under the same irradiation condition and time. The cell temperature of 42-50 °C was reported to cause irreversible cell death or tissue damage (necrosis, microvascular thrombosis, or ischaemia), but it was not sufficient for an effective photothermal therapy, which was generally achieved by laser with local temperature elevation > 60 °C.51These results hinted that the recombined WSCP as a photosensitizer might exert a dual light effect: photodynamic and photothermal effect in the cancer phototherapy. Nevertheless, this low-temperature photothermal effect of recombinant WSCP could be potential for low-temperature photothermal therapy with limited thermal injury to normal tissues by thermal diffusion and might be exploited in combination of immune- therapy.26The photothermal stability of the recombinant WSCP was then investigated and it was found that they were extraordinarily stable (FIG. IE). After four cycles of heating (irradiation with red light to 48 °C) and cooling, the photothermal conversion efficency (16.4% calculated according to reported methods52,53) did not obviously deteriorate. This extraordinary photothermal stability distinguished recombinant WSCP from the majority of organic photosensitizers (porphyrins and chlorins) in PDT.

[0238] EXAMPLE 4— STORAGE STABILITY

[0239] The light and oxygen sensitivity is an intrinsic physicochemical property of photosensitizers. It is not supprising that most photosensitizers are chemically unstable for storage at room temperature without shielding from light, which contributes as a minor fraction to the slow progress of PDT for clinical cancer treatment. The tetrameric WSCP complex was reported to be extraordinarily stable (up to 100 °C)42We studied the storage stability of recombinant WSCP and compared it with free chlorophylls in water and in MeOH (FIG. 7) upon ambient conditions. As shown in FIG. IF, the WSCP solution remained green after storage for 28 days at ambient temperature under normal room light condition, while the dark green color of free chlorophylls faded quickly within a day. The superior stability of recombinant WSCP would be very important to the development of WSCP as a photosensitizer for PDT.

[0240] EXAMPLE 5— CELL KILLING ASSAY OF WSCP FOR PDT

[0241] The results from the physicochemical studies of the recombinant WSCP were very supportive of WSCP as an efficient and stable photosensitizer to generate singlet oxygen. To verify the efficacy of WSCP as a photosensitizer for PDT, cell killing experiments were carried out using HeLa cells as the model (FIG. 2A). HeLa cells were incubated in the presence or absence of high concentration of recombinant WSCP (750 «g / mL) in the darkness for 24 h and then treated with or without 660 nm red light (7.0 mW / cm2) irradiation for 15 min, respectively. The microscopic visualization revealed that the HeLa cells maintained a good morphology when only exposure to light irradiation (FIGs. 2A-2C) or incubation with high concentration of WSCP in the darkness (FIGs. 2A-2B). In contrast, obvious morphological changes including condensed cytoplasm and floating were observed if both WSCP and light were simultaneously present (FIGs. 2A-2D), which demonstrated that recombinant WSCP as a photosensitizer was effective for cell killing.

[0242] Next, a series of cell experiments were carried out using the MTT assay to further quantify the photocytotoxicity of the recombinant WSCP towards HeLa cells. HeLa cells were incubated with WSCP in the dark for 24 h and exposed upon 660 nm red light irradiation for 5, 15 and 30 min, respectively (FIG. 10). As shown in FIG. 2B, ICso value was strongly correlated to the light irradiation time: 44.11 «g / mL (5 min), 29.42 / g / mL (15 min), and 19.72 / g / mL (30 min). Without light irradiation, the ICso value was larger than the control limit >750 «g / mL, which suggested the extremely low dark-cytotoxicity of WSCP. The effect of light density (7.0, 20.6, and 63.3 mW / cm2) on photocytotoxicity of WSCP was also studied (FIG. 11 and FIG. 2C) and it was found that the stronger optical density led to higher cytotoxicity: ICso 54.92 Hg / rnL (7.0 mW / cm2), 36.85 / / g / mL (20.6 mW / cm2), 19.72 / / g / mL (63.3 mW / cm2), respectively. It was noted that optical density had little impact on the cell viability when concentration of WSCP was too low (23 «g / mL) or too high (188 «g / mL) (FIG. 2C). These results proved that recombinant WSCP was an efficient photosensitizer under the cell culturing conditions for generating singlet oxygen to induce cell death.

[0243] EXAMPLE 6— COLONY FORMATION ASSAY

[0244] A cell colony formation assay was performed to assess the anti-proliferation effect of the recombinant WSCP as a photosensitizer of PDT on the HeLa (FIG. 2D) and A549 (FIG. 8) cell lines. Cells were treated with WSCP (50, 25, 12.5, 6, and 3 pg / mL) and irradiated with 660 nm light (31.8 mW / cm2for 15 min) and thereafter were incubated for additional 14 days in the absence of WSCP. The results show that cells treated with 50 pg / mL WSCP, and irradiation lost the proliferation ability (no colony formation), while 25 pg / mL and 12.5 pg / mL WSCP and light irradiation could substantially inhibit the colony formation. Treatments of low concentrations of WSCP (6 and 3 pg / mL) did not give rise to significant inhibition. These results indicated that the photo-induced WSCP therapy could prevent cancer cell proliferation, but its effect was dose-dependent. Additionally, the control experiment (with WSCP alone in the absence of light irradiation) once again confirmed no dark toxicity of the WSCP.

[0245] EXAMPLE 7— CELL MIGRATION ASSAY

[0246] The anti -migration ability of WSCP was examined on HeLa (FIG. 2E) and A549 (FIG. 9) cells by the scratch wound-healing assay. Comparable cell migration into scratched areas could be observed in the blank group (no WSCP) and the group with WSCP but without light irradiation. In contrast, the group with both WSCP and light irradiation had a larger scratched area, which indicated that the recombinant WSCP significantly inhibited the wound-healing and invasion abilities of cancer cells upon light irradiation.

[0247] EXAMPLE 8— EFFECT OF ROS SCAVENGER

[0248] Since PDT generates the deadly cell-killing reactive oxygen species (ROS) such as singlet oxygen and hydroxyl radicals, it is expected that ROS scavengers would inhibit the reactivity of ROS and thus increase the cell viability even in the presence of light irradiation. N-acetyl-L-cysteine (NAC) was used as the ROS scavenger and its effect was examined on the HeLa cells that were treated with recombinant WSCP and red light (FIG. 2F). The experimental results showed that NAC could significantly increase the cell viability by 20- 50% with higher ICso values (27.94 pg / mL to 87.65 pg / mL), which was supportive of that reactive oxygen species generated by WSCP on light irradiation was responsible for the cellkilling ability.

[0249] EXAMPLE 9— CELL KILLING ASSAY AGAINST OTHER CELL LINES

[0250] In principle, PDT can be used for treatment of all kinds of cancers because singlet oxygen (generated in PDT) indiscriminately kills all types of cancer cells, which is a major characteristic of PDT advantageous over chemotherapy that relies on the selective and specific binding of the protein and drug molecules. Therefore, PDT using the recombinant WSCP as the photosensitizer could be used to induce cell death of different cell lines. Six cell lines (HeLa, A549, SKOV3, Hep G2, 4T1 and L02) were selected for the MTT assays (FIG. 2G and FIG. 12-FIG. 18) and their ICso values (ca. 50 «g / mL) were found to be ca. 2.5 times higher than that of HeLa cells (ca. 20 «g / mL). The cause for such difference remains unknown. Surprisingly, no obvious photocytotoxicity against normal liver cells (L02 cells) was observed if the concentration of WSCP was below 50 / g / mL (ICso 112.1 «g / mL). The unexpected selectivity of cancer cells over normal cells might be due to 1) different cell sensitivity to singlet oxygen and 2) the difference in possible cellular uptake of the recombinant WSCP (FIG. 3D and FIG. 22). This selectivity can reduce the damage to normal tissues and would be advantageous and significant in the clinical application of PDT with WSCP. Moreover, the controlled experiments indicated that WSCP (up to 3 mg / mL) was nontoxic against these six cell lines for 48 h in the dark (FIG. 13- FIG. 19).

[0251] EXAMPLE 10— INTRACELLULAR REACTIVE OXYGEN SPECIES (ROS) GENERATION

[0252] The aforementioned results (FIGs. 2A-2G) have demonstrated the effectiveness of recombinant WSCP as a photosensitizer for light-induced cell death. The ROS from WSCP / light could be generated in the extracellular fluid, inside the cells (if cellular uptake of WSCP indeed occurred), or both. In order to probe the possibility of intracellular ROS generation for killing the cells, confocal imaging and flow cytometric analysis were used to investigate the photodynamic effect of the recombinant WSCP on the intracellular ROS level of live cells by using 2',7'-dichlorofluorescin diacetate (DCF-DA) as the ROS-responsive dyes. The intensity of green, fluorescent light is proportional to the quantity of in situ generated intracellular ROS. Confocal images (FIG 3A and FIG. 20) revealed that WSCP and light together were essential and able to generate significant amounts of intracellular ROS, which was comparable to the level from treatment of hydrogen peroxide (H2O2). Flow cytometric analysis is a more quantitative approach to evaluate the photo-induced intracellular ROS generation ability (FIG. 3B). It was found that the combination of WSCP and red light (660 nm) could significantly increase the percentage (62.2%) of HeLa cells with intracelluar ROS (controlled results: 33.3%, 39.7% with light, 11.4% with NAC, 49.0% with WSCP, 20.6% with WSCP / NAC, and 32.4% with WSCP / NAC / light), which demonstrated the ability of WSCP / light to generate intracelluar ROS for killing the cells. This finding was significant to the understanding of the mechanism of action: the combination of WSCP and light was able to generate extracellular and intracellular ROS for cell killing.

[0253] EXAMPLE 11— CELLULAR UPTAKE ANALYSIS

[0254] To further support that WSCP / light could generate ROS inside the cells, cellular uptake experiments were performed with WSCP. The fluorescence emission property of WSCP (FIG. 1A and FIG. 21) enabled a straightforward in vitro study of their cellular uptake using flow cytometry (FIG. 3C). After incubation with WSCP for 30 min, 2.15% HeLa cells contained WSCP, indicating the cellular uptake process of the recombinant WSCP through endocytosis. After incubation with WSCP for 24 h, all HeLa cells (100%) contained WSCP, which further supported the time-dependent endocytosis. Confocal microscope images (FIG. 3D) indicated the time-dependent cellular uptake process of WSCP by tumor cells (HeLa) and normal liver cells (L02) (FIG. 22), respectively. With the extension of coincubation time, more and more WSCP (red color) were observed in cytoplasm (green color) of HeLa cells: only weak intracellular red fluorescence was found after 30 min incubation with WSCP, and the intensity of red fluorescence increased significantly after 2 and 24 h. It was noteworthy that cellular uptake of WSCP was lower in L02 than in HeLa cells (24 h coincubation), which could partially explain the selectivity of WSCP towards cancer and normal cells (FIG. 2G). Additionally, the cell membrane and nuclei of the unfixed HeLa cells with intracellular WSCP were damaged significantly upon 647 nm light excitation (FIG. 23), which was in agreement with in situ generation of extracellular and intracellular ROS for cell killing.

[0255] EXAMPLE 12— IN VIVO ANTICANCER ACTIVITY

[0256] Encouraged by the excellent photo-induced cytotoxicity of WSCP against cancerous cells, its in vivo phototherapeutic efficacy in tumor suppression was evaluated. Mice bearing B16F10 melanoma xenograft as a subcutaneous tumor model was used for the phototherapeutic study (FIGs. 4A-4H). Taking advantage of the biodegradability and photo / thermostability of recombinant WSCP in vivo, both intertumoral injection (z. ) and intravenous injection (z.v.) were used to evaluate its phototherapeutic efficacy and systemic toxicity (FIG. 4A). Body weight and tumor size were monitored every 3 days for 14 consecutive days (FIG. 4B and FIG. 4C).

[0257] As shown in FIG. 4B, the mouse body weight (18 g) did not vary significantly during the whole experimental period, which suggested the negligible systemic toxicity of WSCP. For the mice treated with saline, light irradiation or WSCP (z.t.) alone, only limited or even no tumor-growth suppression was observed: the tumor volumes of nearly all mice in these three groups were over 1000 mm3at day 14 from less than 100 mm3at day 0. In contrast, mice treated with WSCP (z.t. or z.v.) plus 5 minutes light irradiation at 4 h post injection were found to have significantly slow tumor growth and obvious stop-growing overall trend after three times of treatment from day 9 (FIG. 4C). Moreover, nearly all tumors from the i.t. group maintained at a small volume (< 100 mm3) over the whole therapeutic process and one of tumor was even eliminated after 14 days of treatment (FIG. 4D). The weights (FIG. 4E) and images of tumor tissues (FIG. 4F) gave the same results: the tumor volumes of treated groups were smaller than those of the control group. This is direct evidence of in vivo efficacy of recombinant WSCP as a photosensitizer for tumor suppression. The result shows the slight difference of therapeutic performance between the i.t. and i.v. injection methods, the latter of which (z.v.) showed lower efficacy presumably due to in vivo proteolysis and slow intravenous infusion.

[0258] To evaluate the general impact of PDT on healthy tissues and organs, the histological evaluation was carried out. The main organ tissues (heart, liver, spleen, lung, and kidney) of all mice were collected and measured. Comparison of main organ index (FIG. 4G) and hematoxylin and eosin (H&E) staining tissue slices (FIG. 4H) from four experimental groups with the control group indicated no obvious drug-induced injury on these tissues, supportive of great biocompatibility and nontoxicity of recombinant WSCP as photosensitizers for PDT. These findings greatly facilitate the clinical applications of PDT using WSCP as a stable, efficient, water-soluble photosensitizer for tumor ablation.

[0259] In summary, the present invention established the water-soluble recombinant WSCP complex as an efficient and biocompatible photosensitizer for in vitro and in vivo photodynamic therapy for cancers. The recombinant WSCP features the integration of water- soluble biopolymers and organic photosensitizers (chlorophylls). The formation of tetrameric protein complexes greatly stabilizes the unstable chlorophylls with retention of their ability as a photosensitizer to generate reactive oxygen species (ROS, singlet oxygen) upon light irradiation for PDT. The use of WSCP for PDT overcomes many existing limitations of photosensitizers including water-solubility, photo / thermostability, dark-toxicity, biocompatibility, and biodegradability, which will open the door to wider clinical applications.

[0260] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and / or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.

[0261] REFERENCES

[0262] 1. Li, X., Lovell, J. F., Yoon, J. & Chen, X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nature Reviews Clinical Oncology 17, 657-674 (2020).

[0263] 2. Dolmans, D. E. J. G. J., Fukumura, D. & Jain, R. K. Photodynamic therapy for cancer.

[0264] Nature Reviews Cancer 3, 380-387 (2003). https: / / doi.org: 10.1038 / nrcl071

[0265] 3. Karges, J. Clinical development of metal complexes as photosensitizers for photodynamic therapy of cancer. Angew. Chem. Int. Ed. 61, e202112236 (2022).

[0266] 4. Grzybowski, A., Sak, J. & Pawlikowski, J. A brief report on the history of phototherapy.

[0267] Clinics in Dermatology 34, 532-537 (2016).

[0268] 5. Wan, M. T. & Lin, J. Y. Current evidence and applications of photodynamic therapy in dermatology. Clin. Cosmet. Investig. Dermatol. 7, 145-163 (2014). https: / / doi.org: 10.2147 / CCID.S35334

[0269] 6. Lee, Y. & Baron, E. D. Photodynamic therapy: current evidence and applications in dermatology. Semin. Cutan. Med. Surg. 30, 199-209 (2011). https: / / doi.org: 10.1016 / j.sder.2011.08.001

[0270] 7. Baskaran, R., Lee, J. & Yang, S. G. Clinical development of photodynamic agents and therapeutic applications. Biomater Res 22, 25 (2018). https: / / doi.org: 10.1186 / s40824- 018-0140-z

[0271] 8. O’Connor, A. E., Gallagher, W. M. & Byrne, A. T. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochemistry and photobiology 85, 1053-1074 (2009).

[0272] 9. Luo, D., Carter, K. A., Miranda, D. & Lovell, J. F. Chemophototherapy: An Emerging

[0273] Treatment Option for Solid Tumors. Advanced Science 4, 1600106 (2017). https: / / doi.org:https: / / doi.org / 10.1002 / advs.201600106

[0274] 10. Ng, C. W ., Li, J. & Pu, K. Recent Progresses in Phototherapy- Synergized Cancer

[0275] Immunotherapy. Advanced Functional Materials 28, 1804688 (2018). https: / / doi.org:https: / / doi.org / 10.1002 / adfm.201804688

[0276] 11. Buytaert, E., Dewaele, M. & Agostinis, P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1776, 86-107 (2007). https: / / doi.org:https: / / doi.org / 10.1016 / j.bbcan.2007.07.001

[0277] 12. Van Straten, D., Mashayekhi, V., De Bruijn, H. S., Oliveira, S. & Robinson, D. J.

[0278] Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers 9, 19 (2017).

[0279] 13. Ethirajan, M., Chen, Y., Joshi, P. & Pandey, R. K. The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chemical Society Reviews 40, 340-362 (2011).

[0280] 14. Zhao, X., Liu, J., Fan, J., Chao, H. & Peng, X. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application. Chemical Society Reviews 50, 4185-4219 (2021).

[0281] 15. Lan, M. et al. Photosensitizers for photodynamic therapy. Advanced healthcare materials

[0282] 8, 1900132 (2019).

[0283] 16. Qi, G. B., Gao, Y. J., Wang, L. & Wang, H. Self-assembled peptide-based nanomaterials for biomedical imaging and therapy. Advanced Materials 30, 1703444 (2018).

[0284] 17. Brandis, A. S., Salomon, Y. & Scherz, A. in Chlorophylls and Bacteriochlorophylls

[0285] Advances in Photosynthesis and Respiration Ch. Chapter 32, 461-483 (2006). 18. Park, J. M., Hong, K.-L, Lee, H. & Jang, W.-D. Bioinspired applications of porphyrin derivatives. Accounts of chemical research 54, 2249-2260 (2021).

[0286] 19. Chinna Ayya Swamy, P. et al. Near Infrared (NIR) absorbing dyes as promising photosensitizer for photo dynamic therapy. Coord. Chem. Rev. 411, 213233 (2020). https: / / doi.org:https: / / doi.org / 10.1016 / j.ccr.2020.213233

[0287] 20. Liu, T. W ., Huynh, E., MacDonald, T. D. & Zheng, G. in Cancer Theranostics 229-254

[0288] (Elsevier, 2014).

[0289] 21. Spikes, J. D. New trends in photobiology: Chlorins as photosensitizers in biology and medicine. Journal of Photochemistry and Photobiology B: Biology 6, 259-274 (1990). https: / / doi.org:https: / / doi.org / 10.1016 / 101 l-1344(90)85096-F

[0290] 22. Cai, J.-Q., Liu, X.-M., Gao, Z.-J., Li, L.-L. & Wang, H. Chlorophylls derivatives:

[0291] Photophysical properties, assemblies, nanostructures and biomedical applications. Materials Today 45, 77-92 (2021).

[0292] 23. Lo, P. C. et al. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer. Chem. Soc. Rev. 49, 1041-1056 (2020). https : / / doi . org : 10.1039 / c9cs00129h

[0293] 24. Dougherty, T. J., Kaufman, J. E., Goldfarb, A., Weishaupt, K. R. & Mittleman, A.

[0294] Photoradiation Therapy for Treatment of Malignant Tumors. Cancer Research 38, 2628-2635 (1978).

[0295] 25. Hamblin, M. R. Photodynamic Therapy for Cancer: What's Past is Prologue.

[0296] Photochemistry and Photobiology 96, 506-516 (2020). https: / / doi.org: 10.1111 / php.13190

[0297] 26. Deng, X., Shao, Z. & Zhao, Y. Solutions to the drawbacks of photothermal and photodynamic cancer therapy. Advanced Science 8, 2002504 (2021).

[0298] 27. Niculescu, A.-G. & Grumezescu, A. M. Photodynamic Therapy — An Up-to-Date Review.

[0299] Applied Sciences 11, 3626 (2021).

[0300] 28. Zhong, S., Bird, A. & Kopec, R. E. The Metabolism and Potential Bioactivity of

[0301] Chlorophyll and Metallo-chlorophyll Derivatives in the Gastrointestinal Tract. Mol Nutr Food Res 65, e2000761 (2021). https: / / doi.org: 10.1002 / mnfr.202000761

[0302] 29. Pucci, C. et al. Light-Activated Biomedical Applications of Chlorophyll Derivatives.

[0303] Macromolecular Bioscience 21, 2100181 (2021).

[0304] 30. Grimm, B., Porra, R. J., Rudiger, W. & Scheer, H. Chlorophylls and

[0305] Bacteriochlorophylls: Biochemistry, Biophysics, Functions and Applications. (2006).

[0306] 31. Pan, L. et al. A novel composite hydrogel initiated by Spinacia oleracea L. extract on

[0307] Hela cells for localized photodynamic therapy. Mater Sci Eng C Mater Biol Appl 75, 1448-1455 (2017). https: / / doi.org:10.1016 / j.msec.2017.03.021

[0308] 32. Zhou, H. et al. Plant-derived chlorophyll derivative loaded liposomes for tri-model imaging guided photodynamic therapy. Nanoscale 11, 19823-19831 (2019). https: / / doi.org: 10.1039 / C9NR06941K

[0309] 33. Pham, T. C., Nguyen, V.-N., Choi, Y ., Lee, S. & Yoon, J. Recent Strategies to Develop

[0310] Innovative Photosensitizers for Enhanced Photodynamic Therapy. Chemical Reviews 121, 13454-13619 (2021). https: / / doi.org:10.1021 / acs.chemrev. lc00381

[0311] 34. Murata, T., Toda, F., Uchino, K. & Yakushiji, E. Water-soluble chlorophyll protein of

[0312] Brassica oleracea var. botrys (cauliflower). Biochimica et Biophysica Acta (BBA)- Bioenergetics 245, 208-215 (1971).

[0313] 35. Palm, D. M. et al. Chlorophyll a / b binding-specificity in water-soluble chlorophyll protein. Nature Plants 4, 920-929 (2018). 36. Yakushiji, E., Uchino, K., Sugimura, Y., Shiratori, I. & Takamiya, F. Isolation of water- soluble chlorophyll protein from the leaves of Chenopodium album. Biochimica et biophysica acta 75, 293-298 (1963).

[0314] 37. Anderson, I. & Robertson, D. Role of carotenoids in protecting chlorophyll from photodestruction. Plant Physiology 35, 531 (1960).

[0315] 38. Palm, D. M. et al. Water-soluble chlorophyll protein (WSCP) stably binds two or four chlorophylls. Biochemistry 56, 1726-1736 (2017).

[0316] 39. Takahashi, S., Uchida, A., Nakayama, K. & Satoh, H. The C-terminal extension peptide of non-photoconvertible water-soluble chlorophyll-binding proteins (Class II WSCPs) affects their solubility and stability: comparative analyses of the biochemical and chlorophyll-binding properties of recombinant Brassica, Raphanus and Lepidium WSCPs with or without their C-terminal extension peptides. The protein journal 33, 75-84 (2014).

[0317] 40. Horigome, D. et al. Structural mechanism and photoprotective function of water-soluble chlorophyll-binding protein. J. Biol. Chem. 282, 6525-6531 (2007).

[0318] 41. Takahashi, S. et al. Molecular cloning, characterization and analysis of the intracellular localization of a water-soluble Chl-binding protein from Brussels sprouts (Brassica oleracea var. gemmifera). Plant Cell Physiol. 53, 879-891 (2012).

[0319] 42. Palm, D. M. et al. Stability of Water-Soluble Chlorophyll Protein (WSCP) Depends on

[0320] Phytyl Conformation. ACS Omega 4, 7971-7979 (2019). https: / / doi.org: 10.1021 / acsomega.9b00054

[0321] 43. Dodge, N. et al. Water-soluble chlorophyll-binding proteins from Brassica oleracea allow for stable photobiocatalytic oxidation of cellulose by a lytic polysaccharide monooxygenase. Biotechnol Biofuels 13, 192 (2020). https: / / doi.org: 10.1186 / sl3068- 020-01832-7

[0322] 44. Lemke, O. & Gbtze, J. P. On the Stability of the Water-Soluble Chlorophyll-Binding

[0323] Protein (WSCP) Studied by Molecular Dynamics Simulations. The Journal of Physical Chemistry B 123, 10594-10604 (2019). https: / / doi.org: 10.1021 / acs.jpcb.9b07915

[0324] 45. Bednarczyk, D., Takahashi, S., Satoh, H. & Noy, D. Assembly of water-soluble chlorophyll-binding proteins with native hydrophobic chlorophylls in water-in-oil emulsions. Biochim Biophys Acta 1847, 307-313 (2015). https: / / doi.org: 10.1016 / j.bbabio.2014.12.003

[0325] 46. Spikes, J. D. & Bommer, J. C. Chlorophyll and related pigments as photosensitizers in biology and medicine. (1991).

[0326] 47. Schmidt, K., Fufezan, C., Krieger-Liszkay, A., Satoh, H. & Paulsen, H. Recombinant water-soluble chlorophyll protein from Brassica oleracea var. Botrys binds various chlorophyll derivatives. Biochemistry 42, 7427-7433 (2003).

[0327] 48. Li, M. et al. Controlling synthetic membraneless organelles by a red-light-dependent singlet oxygen-generating protein. Nature Communications 13, 3197 (2022). https: / / doi.org: 10.1038 / s41467-022-30933-0

[0328] 49. Xie, J. et al. Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies. Chemical Society Reviews (2021).

[0329] 50. Gan, S. et al. Size Optimization of Organic Nanoparticles with Aggregation-Induced

[0330] Emission Characteristics for Improved ROS Generation and Photodynamic Cancer Cell Ablation. Small, 2202242 (2022).

[0331] 51. Knavel, E. M. & Brace, C. L. Tumor ablation: common modalities and general practices.

[0332] Tech Vase Interv Radiol 16, 192-200 (2013). https: / / doi.org: 10.1053 / j.tvir.2013.08.002 , Q. et al. Hydrophilic Cu9S5 nanocrystals: a photothermal agent with a 25.7% heat conversion efficiency for photothermal ablation of cancer cells in vivo. ACS nano 5, 9761-9771 (2011). D. et al. NIR light-driving barrier-free group rotation in nanoparticles with an 88.3% photothermal conversion efficiency for photothermal therapy. Advanced Materials 32,

[0333] 1907855 (2020).

Claims

CLAIMSWe claim:

1. A method of photodynamic therapy (PDT) for treating cancer comprising administering to a subject in need of such therapy an effective amount of a water-soluble chlorophyll protein (WSCP) complex and irradiating cancer by exposing the WSCP complex to an excitation light.

2. The method of claim 1, wherein the WSCP complex comprises a WSCP and 2-4 chlorophylls.

3. The method of claim 1, wherein the WSCP complex serves as a stable photosensitizer to generate reactive oxygen species for inducing cell death.

4. The method of claim 2, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1, a biologically-active fragment thereof, a variant thereof, or an amino acid sequence sharing at least 95% identity with SEQ ID NO: 1.

5. The method of claim 2, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

6. The method of claim 1, wherein the cancer is selected from fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma,medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma.

7. The method of claim 1, wherein the cancer is selected from cervical cancer, lung cancer, ovarian cancer, liver cancer, and breast cancer.

8. The method of claim 1, wherein the excitation light has a wavelength of about 600 nm to 900 nm.

9. The method of claim 8, wherein the excitation light has a wavelength of about 600 nm to 700 nm.

10. The method of claim 1, wherein the WSCP complex is administered intravenously, intraperitoneally, intramuscularly, intratumorally, intraarterially, topically, or orally.

11. A pharmaceutical composition for PDT comprising a water-soluble chlorophyll protein (WSCP) complex, wherein the WSCP complex comprises a WSCP and 2-4 chlorophylls.

12. The pharmaceutical composition of claim 11, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1, a biologically-active fragment thereof, a variant thereof, or an amino acid sequence sharing at least 95% identity with SEQ ID NO: 1.

13. The pharmaceutical composition of claim 11, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

14. A method for photodynamically damaging cancer cells, the method comprising contacting the cancer cells with the pharmaceutical composition of claim 12 and irradiating the cancer cells with an excitation light.

15. The method of claim 14, wherein the excitation light has a wavelength of about 600 nm to 700 nm.

16. The method of claim 14, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1, a biologically-active fragment thereof, a variant thereof, or an amino acid sequence sharing at least 95% identity with SEQ ID NO: 1.

17. The method of claim 14, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

18. The method of claim 14, wherein the cancer cells are selected from fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma.

19. A method for inhibiting the proliferation of cancer cells, the method comprising contacting the cancer cells with an effective amount of a water-soluble chlorophyll protein (WSCP) complex comprising a WSCP and 2-4 chlorophylls; and irradiating the cancer cells with an excitation light having a wavelength of about 600-900 nm.

20. The method of claim 19, wherein the WSCP comprises the amino acid sequence of SEQ ID NO: 1.

Citation Information

Patent Citations

  • Photodynamic therapy and diagnosis

    WO2022112537A1